Pyrimidine compound as well as preparation method, pharmaceutical composition and application thereof
By designing a novel EGFR inhibitor of indole ring skeleton with hydrophilic side chains and skeleton transitions, the problem of resistance to EGFR C797S mutations by existing EGFR inhibitors is solved, and effective inhibition of a variety of drug-resistant mutants is achieved. , suitable for a variety of tumor treatments.
Patent Information
- Application Number
- CN202310582722.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing EGFR inhibitors are not effective in the face of EGFR C797S mutations, leading to drug resistance problems, lack of effective alone drugs for this mutation, and the development of multiple structural types of drug candidates is required to cope with drug resistance.
A series of novel EGFR inhibitors with indole ring skeletons were designed to improve the inhibitory activity of EGFRL858R/T790M/C797S and EGFRdel19/T790M/C797S mutant enzymes by introducing hydrophilic side chains and skeleton transitions, which was better than the positive controls. The medicine may remain flat.
This pyrimidine compound can effectively inhibit a variety of EGFR drug-resistant mutants at nanomolar concentration levels. It is suitable for the preparation of anti-tumor drugs. It has a wide range of applications and is highly applicable to the preparation method of compound, which is convenient for structural expansion.
Smart Images

Figure CN119019367A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a pyrimidine compound and a preparation method, a pharmaceutical composition and application thereof, and in particular to a pyrimidine compound with anti-tumor activity and a preparation method, a pharmaceutical composition and application thereof. Background Art
[0002] EGFR (Epidermal Growth Factor Receptor) is a receptor for epidermal growth factor (EGF) cell proliferation and signal transduction. It belongs to the ErbB receptor family and is also known as HER1 and ErbBl. EGFR is a glycoprotein, a tyrosine kinase receptor, a transmembrane receptor located on the cell membrane surface, with a molecular weight of 170KDa. EGFR is activated by binding to its ligands EGF and TGFa (transforming growth factorα), which in turn activates the kinase pathway in the cell, causing phosphorylation of downstream MAPK, Akt and JNK pathways, inducing cell proliferation. Overexpression of EGFR can cause abnormal activation of downstream signals, and is therefore associated with the inhibition of tumor cell proliferation, angiogenesis, tumor invasion, metastasis and apoptosis.
[0003] At present, the development of EGFR small molecule inhibitor drugs has gone through four generations. Many patients will develop resistance after taking the first-generation EGFR inhibitors for a few months, mainly caused by the T790M (threonine replaces methionine) mutation. The second-generation EGFR inhibitors developed for this mutation need to target both mutant and non-mutated EGFR targets, so there are disadvantages of insufficient therapeutic doses and large toxic side effects. In order to overcome the above problems, the third-generation EGFR inhibitors developed, such as osimertinib, the first drug for EGFR T790M mutation, will still develop resistance in some patients after 9 to 14 months of treatment, mainly caused by the EGFR C797S mutation (cysteine CYS797 becomes serine SER797). This is because the covalent binding bond of osimertinib cannot bind to the target cysteine, resulting in off-target.
[0004] CN115650958A discloses a 2-aminopyrimidine EGFR small molecule inhibitor, which has a good inhibitory effect on various EGFR mutants. However, due to the current lack of effective EGFR inhibitors for the EGFR C797S mutation alone, it is urgent to solve its drug resistance. Therefore, it is still necessary to develop candidate drugs of various structural types to address other drug resistance problems. Summary of the invention
[0005] Objectives of the invention: The first objective of the present invention is to provide a pyrimidine compound with anti-tumor activity, the second objective is to provide a method for preparing the pyrimidine compound, the third objective is to provide a pharmaceutical composition comprising the pyrimidine compound, and the fourth objective is to provide the application of the pyrimidine compound and its pharmaceutical composition.
[0006] Technical solution: The pyrimidine compound of the present invention has a structure of formula (I), and also includes pharmaceutically acceptable salts, stereoisomers, deuterated compounds or mixtures thereof:
[0007]
[0008] in:
[0009] m is selected from 0 or 1; when m is 1, M 1 C, M 2 is CH; when m is 0, M 1 is N;
[0010] X is selected from O or NH;
[0011] A is selected from unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 Aryl, OR 2 , SR 2 NR 2 R 3 ; The heteroatom is N, O or S;
[0012] R 1 Selected from hydroxyl, cyano, halogen, nitro, C 1-6 Alkyl, C 2-8 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 6-10 Aryloxy, heteroaryloxy, (C 3-10 Cycloalkyl)-oxy, halo (C 1-6 Alkyl), hydroxyl (C 1-6 Alkyl), amino (C 1-6 Alkyl), C 1-6 Alkylamino-C 1-6 Alkoxy-, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-(C 1-6 Alkyl)-, C 3-10 Cycloalkyl-(C 1-6 Alkoxy), -OCD3, -NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 、-O(C=O)R 1-12 、-S(=O)2NR 1-13 R 1-14 、-NR 1-15 S(=O)2R 1-16 、-S(=O)2R 1-17 or -P(=O)R 1-18 R 1-19 , unsubstituted or R 1-1 Substituted C 6-10 Aryl, C 6-10 Aryl-(C 1-6 alkyl)-, unsubstituted or R 1-2 Substituted C 6-10 Aryl-(C 1-6 alkoxy)-, heterocycloalkyl, heterocycloalkyl-(C 1-6 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-6 alkyl)- or heteroaryl-(C 1-6 The heterocycloalkyl group is a 4- to 10-membered heterocycloalkyl group having 1 to 4 heteroatoms; the heteroaryl group is a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms; R 1-1 ~R 1-3 Any one independently selected from C 1-4 Alkyl, hydroxyl (C 1-4 alkyl)-, halogen, cyano, hydroxyl, C 1-4 Alkylamino, C 1-4 Alkoxy or halogenated (C 1-4 Alkyl)-; R 1-4 ~R 1-19 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 The heteroatom is N, O or S;
[0013] R 2 Selected from C 3-10 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-6 Alkyl, unsubstituted or R 2-2 Substituted C 6-10 Aryl, 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms; R 2-1 , R 2-2are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O)2NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O)2R 2 -1-13 、-S(=O)2R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 The heteroatom is N, O or S;
[0014] R 3 Selected from hydrogen or C 1-4 alkyl;
[0015] R 4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 Alkyl)-; R 4-1 Selected from halogen, hydroxyl, NR 4-1-1 R 4-1-2 or cyano; R 4-1-1 , R 4-1-2 Any one independently selected from hydrogen or C 1-6 alkyl;
[0016] R 5 , R 6 independently selected from hydrogen, methyl or ethyl;
[0017] R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl having 1 to 4 heteroatoms; R 7-1 Selected from halogen, cyano, hydroxyl, NR7-1-1 R 7-1-2 , C 1-6 Alkyl or C 1-6 Alkoxy; R 7-1-1 , R 7-1-2 Any one independently selected from hydrogen or C 1-6 Alkyl; the heteroatom is N, O or S;
[0018] R 8 Selected from hydrogen or C 1-4 alkyl;
[0019] R 9 Selected from hydrogen, -NHR 9-1 、-C=ONH2、-C=ONHR 9-1 、-C=ONR 9-1 R 9-2 , -C=ONHO(CH2)nOH, -CH2NH(CH2)nOR 9-1 、-C=ONH(CH2)nNR 9-1 R 9-2 、-CH2R 9-1 , unsubstituted or at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 10 membered heterocycloalkyl, 3 to 10 membered heterocycloalkyl-NR 9-4-1 -, (3- to 10-membered heterocycloalkyl)-(3- to 10-membered heterocycloalkyl)-, 6- to 17-membered spiro heterocyclic group, 6- to 17-membered bridged heterocyclic group, 6- to 17-membered fused heterocyclic group; R 9-1 ~R 9-3 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl, unsubstituted or substituted with one or more R 9-1-1 A 4- to 10-membered heterocycloalkyl group having 1 to 4 substituted heteroatoms, wherein the heteroatoms are N, O or S; R 9-4 Selected from H, halogen, -OH, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -NHR 9-4-1 、-NR 9-4-1 R 9-4-2 , -C 1-4 Alkyl-NR 9-4-1 R 9-4-2 、-NR 9-4-1 R 9 -4-2 -C 1-4Alkyl-NR 9-4-3 R 9-4-4 ; n is an integer selected from 1 to 4; R 9-1-1 , R 9-4-1 ~R 9-4-4 Any one independently selected from hydrogen, C 1-4 alkyl; and when m is 1, R 9 Not hydrogen.
[0020] Preferably, in the structure:
[0021] When A is unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 When the aryl group is C 5-8 Aryl; the heteroatom is N, O or S;
[0022] R 1 Selected from hydroxyl, cyano, halogen, nitro, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 6-10 Aryloxy, heteroaryloxy, (C 3-7 Cycloalkyl)-oxy, halo (C 1-4 Alkyl), hydroxyl (C 1-4 Alkyl), amino (C 1-4 Alkyl), C 1-4 Alkylamino-C 1-4 Alkoxy-, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-(C 1-4 Alkyl)-, C 3-7 Cycloalkyl-(C 1-4 Alkoxy), -OCD3, -NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR 1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 , -O(C=O)R 1-12 、-S(=O)2NR 1-13 R 1-14 、-NR 1-15 S(=O)2R 1-16 、-S(=O)2R 1-17 or -P(=O)R1-18 R 1-19 , unsubstituted or R 1-1 Substituted C 6-10 Aryl, C 6-10 Aryl-(C 1-4 alkyl)-, unsubstituted or R 1-2 Substituted C 6-10 Aryl-(C 1-4 alkoxy)-, heterocycloalkyl, heterocycloalkyl-(C 1-4 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-4 alkyl)- or heteroaryl-(C 1-4 The heterocycloalkyl group is a 4- to 8-membered heterocycloalkyl group having 1 to 3 heteroatoms; the heteroaryl group is a 5- to 8-membered heteroaryl group having 1 to 3 heteroatoms; R 1-1 ~R 1-3 Any one independently selected from C 1-4 Alkyl, hydroxyl (C 1-4 alkyl)-, halogen, cyano, hydroxyl, C 1-4 Alkylamino, C 1-4 Alkoxy or halogenated (C 1-4 Alkyl)-; R 1-4 ~R 1-19 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S;
[0023] When A is OR 2 , SR 2 NR 2 R 3 When R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O)2NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O)2R 2-1-13 、-S(=O)2R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S;
[0024] R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O)2NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O)2R 2-1-13 、-S(=O)2R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S;
[0025] R4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 Alkyl)-; R 4-1 Selected from halogen, hydroxyl, NR 4-1-1 R 4-1-2 or cyano; R 4-1-1 , R 4-1-2 Any one independently selected from hydrogen or C 1-4 alkyl;
[0026] R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or 4- to 8-membered heterocycloalkyl having 1 to 3 heteroatoms; R 7-1 Selected from halogen, cyano, hydroxyl, NR 7-1-1 R 7-1-2 , C 1-4 Alkyl or C 1-4 Alkoxy; R 7-1-1 , R 7-1-2 Any one independently selected from hydrogen or C 1-4 Alkyl; the heteroatom is N, O or S;
[0027] R 9 Selected from hydrogen, -NHR 9-1 、-C=ONH2、-C=ONHR 9-1 、-C=ONR 9-1 R 9-2 , -C=ONHO(CH2)nOH, -CH2NH(CH2)nOR 9-1 、-C=ONH(CH2)nNR 9-1 R 9-2 、-CH2R 9-1 , unsubstituted or at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 7 membered heterocycloalkyl, 3 to 7 membered heterocycloalkyl-NR 9-4-1 -, (3- to 7-membered heterocycloalkyl)-(3- to 7-membered heterocycloalkyl)-, 6- to 14-membered spiro heterocyclic group, 6- to 14-membered bridged heterocyclic group, 6- to 14-membered fused heterocyclic group; R 9-1 ~R 9-3 Any one independently selected from hydrogen, C 1-3 Alkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more R 9-1-1A 4- to 8-membered heterocycloalkyl group having 1 to 3 substituted heteroatoms, wherein the heteroatoms are N, O or S; R 9-4 Selected from H, halogen, -OH, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-3 Alkyl, -NHR 9-4-1 、-NR 9-4-1 R 9-4-2 , -C 1-4 Alkyl-NR 9-4-1 R 9-4-2 、-NR 9-4-1 R 9-4-2 -C 1-4 Alkyl-NR 9-4-3 R 9-4-4 ; n is an integer selected from 1 to 3; R 9-1-1 , R 9-4-1 ~R 9-4-4 Any one independently selected from hydrogen, C 1-4 alkyl; and when m is 1, R 9 Not hydrogen.
[0028] Preferably, in the structure:
[0029] R 4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 Alkyl)-; R 4-1 is selected from fluorine, chlorine, bromine, hydroxyl, methylamine, ethylamine, dimethylamine, diethylamine, n-propylamine or cyano;
[0030] R 5 , R 6 independently selected from hydrogen or methyl;
[0031] R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or 4-8 membered heterocycloalkyl having 1-3 heteroatoms; the heteroatoms are N, O or S;
[0032] R 7-1 is selected from halogen, cyano, hydroxy, methylamino, ethylamino, dimethylamino, diethylamino, propylamino, methyl, ethyl, n-propyl, isopropyl, methoxy or ethoxy;
[0033] R9 Selected from hydrogen, -NHR 9-1 、-C=ONH2、-C=ONHR 9-1 、-C=ONR 9-1 R 9-2 , -C=ONHO(CH2)nOH, -CH2NH(CH2)nOR 9-1 、-C=ONH(CH2)nNR 9-1 R 9-2 、-CH2R 9-1 , unsubstituted or replaced by at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 7 membered heterocycloalkyl, 3 to 7 membered heterocycloalkyl-NR 9-4-1 -, (3- to 7-membered heterocycloalkyl)-(3- to 7-membered heterocycloalkyl)-, 6- to 14-membered spiro heterocyclic group, 6- to 14-membered bridged heterocyclic group, 6- to 14-membered fused heterocyclic group; R 9-1 ~R 9-3 Any one is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, unsubstituted or substituted by one or more R 9-1-1 Substituted morpholine, pyrrole, piperidine, piperazine, pyran; R 9-4 is selected from H, halogen, -OH, -NH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, -CH2Cl, -CH2CH2Cl, -CH2CH2Br, -CH2CH2OH, -CH2OH, -CH2CH2OCH3, -CH2OCH3, -NHCH3, -NHCH2CH3, -NHCH(CH3)2, -N(CH3)2, -N(CH2CH3)2, -NCH3CH2CH3, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -CH2N(CH2CH 3)2, -(CH2)2NH2, -(CH2)2NHCH3, -(CH2)2N(CH3)2, -(CH2)2N(CH2CH3)2, -(CH2)2NCH3CH2CH3, -(CH2)3NH2, -(CH2)3NHCH3, -(CH2)3N(CH3)2, -(CH2)3N(CH2CH3)2, -(CH2)3NCH3CH2CH3, -NCH3CH2CH2N(CH3)2, -NCH3CH2CH2CH2N(CH3)2; n is an integer selected from 1 to 3; R 9-1-1 , R 9-4-1 ~R 9-4-4 are independently selected from hydrogen, methyl, ethyl, isopropyl; and when m is 1, R 9 Not hydrogen.
[0034] Preferably, in the structure:
[0035] When A is unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 When the aryl group is aryl, the substituent is selected from hydroxyl, cyano, halogen, nitro, C 1-4 Alkyl, C 1-4 Alkoxy, hydroxyl (C 1-4 Alkyl)-, amino (C 1-4 Alkyl)-, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-(C 1-4 Alkyl)-, C 3-6 Cycloalkyl-(C 1-4 Alkoxy)-, -OCD3, -NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR 1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 、-O(C=O)R 1-12 、-(S=O)2NR 1-13 R 1-14 、-NR 1-15 (S=O)2R 1-16 、-(S=O)2R 1-17 , -(P=O)(CH3)2, unsubstituted or R 1-1 Substituted phenyl, phenyl-(C 1-4 alkyl)-, unsubstituted or R 1-2 Substituted heterocycloalkyl, heterocycloalkyl-(C 1-4 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-4 alkyl)-; the heterocycloalkyl is a 3- to 10-membered heterocycloalkyl with 1 to 4 heteroatoms; the heteroaryl is a 5- to 10-membered heteroaryl with 1 to 3 heteroatoms; the heteroatom is N, O or S;
[0036] R 1-1 ~R 1-3 Any one is independently selected from hydrogen, methyl, ethyl, hydroxymethyl, hydroxyethyl, fluorine, chlorine, bromine, cyano, hydroxy, methylamino, ethylamino, methoxy, ethoxy, bromomethyl, bromoethyl, chloromethyl or chloroethyl;
[0037] R 1-4 ~R 1-19 Any one is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C3-6 Cycloalkyl or C 3-6 Cycloalkyl-(C 1-4 alkyl);
[0038] When A is OR 2 , SR 2 NR 2 R 3 When R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, methyl, ethyl, isopropyl, n-propyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 、-O(C=O)R 2-1-9 、-S(=O)2NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O)2R 2-1-13 、-S(=O)2R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, C 3-6 Cycloalkyl or C 3-6 Cycloalkyl-(C 1-4 The heteroatom is N, O or S;
[0039] R 3 is selected from hydrogen, methyl or ethyl;
[0040] R 8 is selected from hydrogen, methyl or ethyl.
[0041] Preferably, in the structure:
[0042] A is selected from any of the following groups:
[0043]
[0044] R 9 Selected from any of the following groups:
[0045]
[0046] Preferably, the pyrimidine compound is selected from any one of the following compounds:
[0047]
[0048]
[0049]
[0050]
[0051]
[0052] Given the physicochemical properties of 2-aminopyrimidine EGFR small molecule inhibitors and their effects on EGFR del19 / T790M / C797S The inhibitory activity of the triple mutation needs to be improved. Based on the existing small molecule inhibitors, the present invention introduces a series of hydrophilic side chains. In addition, through skeleton transition, a series of new EGFR inhibitors with indole ring skeletons are finally designed. The designed and synthesized compounds have an effect on EGFR L858R / T790M / C797S and EGFR del19 / T790M / C797S The mutant enzymes all had good inhibitory activity against H-1975 (EGFR L858R / T790M / C797S ) and PC-9 (EGFR del19 / T790M / C797S ) cell proliferation, and the activity was better than or equal to that of the positive control drug.
[0053] Furthermore, the pyrimidine compound forms a pharmaceutically acceptable salt with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, malic acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.
[0054] The preparation method of the pyrimidine compound of the present invention is: compound (I) is obtained by subjecting compound 1 to a substitution reaction with compound 2;
[0055]
[0056] Among them, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , A, M 1 、M 2,X,m are defined as above;
[0057] The pharmaceutically acceptable salt is obtained by reacting the corresponding acid with the compound (I) prepared by the above method to form a salt.
[0058] The pharmaceutical composition of the present invention comprises the pyrimidine compound and a pharmaceutically acceptable carrier.
[0059] Specifically, pharmaceutically acceptable carriers can be added to prepare common pharmaceutical preparations, such as tablets, capsules, syrups, suspensions or injections. The preparations can be added with common pharmaceutical excipients such as flavors, sweeteners, liquid / solid fillers, diluents, etc.
[0060] The pyrimidine compounds and pharmaceutical compositions of the present invention are used in the preparation of EGFR inhibitor drugs, specifically in the preparation of anti-tumor drugs, such as drugs for treating renal cancer, non-small cell lung cancer, prostate cancer, breast cancer, head and neck cancer, etc.
[0061] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0062] The pyrimidine compound can effectively inhibit a variety of EGFR drug-resistant mutants at the molecular and cellular levels, with the inhibitory activity reaching the nanomolar concentration level and optimally reaching the picomolar concentration level; it can be prepared as a drug for treating and / or preventing a variety of tumors and has a wide range of applications; the compound preparation method has strong applicability and is convenient for expanding the compound structure. DETAILED DESCRIPTION
[0063] The technical solution of the present invention is further described below in conjunction with embodiments.
[0064] Example 1: Preparation of Compound S1
[0065]
[0066] The synthetic route and preparation process are as follows:
[0067]
[0068] Step 1: Preparation of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1)
[0069] At 0°C, 1,1-bis(diphenylphosphino)diferronichloridopalladium(II) (37 mg, 0.05 mmol) and potassium acetate (294 mg, 3.0 mmol) were added to a solution of 4-bromo-1H-pyrazole (147 mg, 1.0 mmol) and biboric acid pinacol ester (280 mg, 1.1 mmol) in 1,4-dioxane (6 mL). The mixture was heated to 80°C for 10 hours until the reaction was complete. Water (10 mL) was added to quench the reaction and the mixture was extracted with EA three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 1 (130 mg, 67%). ESI-MS m / z: 195.1 [M+H] + .
[0070] Step 2: Preparation of 1-(cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2)
[0071] At 0°C, NaH (48 mg, 60%, 1.2 mmol) was added to a THF (6 mL) solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-1H-pyrazole (1) (194 mg, 1.0 mmol), and the mixture was moved to room temperature for reaction for 1 hour. The mixture was cooled to 0°C, cyclopropylsulfonyl chloride (211 mg, 1.5 mmol) was added, and the mixture was heated to room temperature for reaction for 4 hours until the reaction was complete. The mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 2 (208 mg, 70%). ESI-MS m / z: 299.1 [M+H] + .
[0072] Step 3: Preparation of intermediate 2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-amine (3)
[0073] At 0°C, dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium (II) (35.5 mg, 0.05 mmol) and 2M aqueous sodium carbonate solution (1 mL, 2.0 mmol) were added to a solution of 1-(cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2) (298 mg, 1.0 mmol) and 2-chloropyrimidin-4-amine (129 mg, 1.0 mmol) in acetonitrile (6 mL). The reaction was completed after heating to 100°C for 4 hours. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 3 (109 mg, 41%). ESI-MS m / z: 266.1 [M+H] + .
[0074] Step 4: Synthesis of 3-chloro-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinoline (4)
[0075] Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of (2R, 3S)-2-methyl-3-((methylsulfonyl)methyl)azetidine (163 mg, 1.0 mmol) and 8-bromo-3-chloro-5-isopropylisoquinoline (285 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 4 (275 mg, 75%). ESI-MS m / z: 367.1 [M+H] + .
[0076] Step 5: Synthesis of 7-bromo-3-chloro-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinoline (5)
[0077] At 0°C, N-bromosuccinimide (NBS) (178 mg, 1.0 mmol) was added to a DMF (6 mL) solution of 3-chloro-5-isopropyl-8-((2R, 3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinoline (4) (367 mg, 1.0 mmol) and the mixture was reacted for 1 hour until the reaction was complete. The reaction solution was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 5 (423 mg, 95%). ESI-MS m / z: 445.0 [M+H] + .
[0078] Step 6: N 1 Synthesis of -(3-chloro-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-7-yl)-N1,N2,N2-trimethylethane-1,2-diamine (6)
[0079] Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of 7-bromo-3-chloro-5-isopropyl-8-((2R, 3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinoline (5) (446 mg, 1.0 mmol) and trimethylethylenediamine (102 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 6 (257 mg, 55%). ESI-MS m / z: 467.2 [M+H] + .
[0080] Step 7: N 3 -(2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)-N 7 -(2-(dimethylamino)ethyl)-5-isopropyl-N 7 Synthesis of 8-(2R,3S)-2-methyl-3-(methylsulfonyl)methyl)azetidin-1-yl)isoquinoline-3,7-diamine (S1)
[0081] At 0℃, N 1 -(3-chloro-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-7-yl)-N 1 ,N 2 ,N 2 -trimethylethane-1,2-diamine (6) (467 mg, 1.0 mmol) and 2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-amine (3) (265 mg, 1.0 mmol) in 1,4-dioxane (5 mL) were added with Brettphos Pd G3 (181 mg, 0.2 mmol) and cesium carbonate (975 mg, 3.0 mmol). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted with EA three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound S1 (397 mg, 57%). 1H NMR(500MHz,DMSO-d6)δ8.93(d,J=0.5Hz,1H),8.67(d,J=5.6Hz,1H),8.49–8.39(m,2 H),8.31(d,J=0.5Hz,1H),8.17(d,J=0.5Hz,1H),7.53(d,J=5.6Hz,1H),6.97(t,J=0. 7Hz,1H),4.09(p,J=6.7Hz,1H),3.95(dd,J=9.2,6.8Hz,1H),3.78(dd,J=9.2,5.6Hz, 1H),3.65–3.43(m,2H),3.41(dd,J=14.8,6.1Hz,1H),3.32–3.25(m,1H),3.16–3.10(m 1H),3.05(s,3H),2.96(s,3H),2.95–2.75(m,2H),2.47–2.40(m,1H),2.36(s,6H),1.88(p,J=5.5H z,1H),1.56–1.50(m,2H),1.42(d,J=6.8Hz,3H),1.25(dd,J=15.0,6.5Hz,6H),1.16–1.10(m,2H). ESI-MS m / z:696.3[M+H] + .
[0082] Compounds S2-S44 were prepared by referring to the method in Example 1.
[0083] Compound S2: 1 H NMR (500MHz, DMSO-d6) δ8.88(d,J=0.5Hz,1H),8.68(d,J=5.6Hz,1H),8.49(s,1H),8.33(dd,J=16. 7,0.5Hz,3H),7.53(d,J=5.6Hz,1H),7.01(t,J=0.7Hz,1H),3.89(dd,J=9.1,5.5Hz,2H),3.64(dd,J =9.1,5.6Hz,2H),3.55–3.48(m,1H),3.45–3.32(m,4H),3.05(s,3H),2.97(s,3H),2.91–2.77(m,1H ),2.62(t,J=5.8Hz,2H),2.47(p,J=6.5Hz,1H),2.36(s,6H),1.30–1.13(m,8H),1.12–0.96(m,2H). ESI-MS m / z:646.3[M+H] + .
[0084] Compound S3: 11H NMR (500 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.65 (d, J = 5.6 Hz, 1H), 8.46 (s, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.08 (d, J = 0.5 Hz, 1H), 7.94 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.96–6.89 (m, 1H), 4.14 (d, J = 3.7 Hz, 2H), 3.90 (dd, J = 9.1, 5.5 Hz, 2H), 3.68 (dd, J = 9.2, 5.6 Hz, 2H), 3.56–3.48 (m, 1H), 3.39–3.23 (m, 4H), 3.05 (s, 3H), 2.94 (s, 3H), 2.62 (td, J = 5.7, 4.6 Hz, 3H), 2.36 (s, 6H), 1.44–1.29 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H), 0.62–0.46 (m, 2H), 0.39–0.23 (m, 2H). ESI-MS m / z: 632.3 [M+H] + 。
[0085] Compound S4: 1 1H NMR (500 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.45–8.38 (m, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.16 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.93 (t, J = 0.7 Hz, 1H), 3.91 (dd, J = 9.2, 5.6 Hz, 2H), 3.68 (dd, J = 9.1, 5.6 Hz, 2H), 3.55–3.10 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.18 (t, J = 5.7 Hz, 2H), 3.05 (s, 3H), 2.97 (s, 3H), 2.72–2.56 (m, 2H), 2.54 (t, J = 5.8 Hz, 2H), 2.36 (s, 6H), 1.55–1.49 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.14 (tdd, J = 9.6, 5.5, 0.8 Hz, 2H). ESI-MS m / z: 682.3 [M+H] + 。
[0086] Compound S5: 11H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.48–8.39 (m, 3H), 8.18 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.86 (t, J = 0.7 Hz, 1H), 6.22 (t, J = 3.7 Hz, 1H), 3.89 (dd, J = 9.2, 5.6 Hz, 2H), 3.64–3.45 (m, 5H), 3.35 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.72–2.54 (m, 4H), 2.26 (s, 6H), 1.52 (tdd, J = 8.7, 5.4, 0.7 Hz, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.14 (tdd, J = 9.6, 5.6, 0.8 Hz, 2H). ESI-MS m / z: 668.3 [M+H] + 。
[0087] Compound S6: 1 1H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.87 (d, J = 0.5 Hz, 1H), 8.63 (d, J = 5.6 Hz, 1H), 8.39 (s, 1H), 8.31–8.25 (m, 1H), 8.13–8.01 (m, 2H), 7.53 (d, J = 5.6 Hz, 1H), 6.81 (d, J = 0.5 Hz, 1H), 4.01–3.88 (m, 5H), 3.65 (dd, J = 9.2, 5.5 Hz, 2H), 3.34 (t, J = 5.7 Hz, 2H), 3.05 (s, 3H), 2.79–2.72 (m, 1H), 2.61–2.46 (m, 8H), 2.35 (s, 6H), 1.18–1.02 (m, 2H), 0.95–0.79 (m, 2H). ESI-MS m / z: 589.3 [M+H] + 。
[0088] Compound S7: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.64 (d, J = 5.6 Hz, 1H), 8.42 (d, J = 0.5 Hz, 1H), 8.31 (t, J = 0.5 Hz, 1H), 8.14–8.03 (m, 2H), 7.53 (d, J = 5.6 Hz, 1H), 6.88–6.81 (m, 1H), 3.97 (dd, J = 9.1, 5.6 Hz, 2H), 3.74 (dd, J = 9.1, 5.6 Hz, 2H), 3.57–3.50 (m, 1H), 3.42–3.26 (m, 4H), 3.09–3.01 (m, 2H), 2.94 (s, 3H), 2.72–2.50 (m, 4H), 2.48–2.31 (m, 5H), 2.36–2.26 (m, 1H), 2.24 (s, 3H), 1.88 (p, J = 5.5 Hz, 1H), 1.83–1.45 (m, 6H), 1.30–1.09 (m, 8H). ESI-MS m / z: 763.3 [M+H] + 。
[0089] Compound S8: 1 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.42 (d, J = 0.8 Hz, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.83 (t, J = 0.7 Hz, 1H), 3.99–3.85 (m, 4H), 3.64 (dd, J = 9.2, 5.6 Hz, 2H), 3.61–3.39 (m, 3H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.95–2.74 (m, 2H), 2.27 (s, 6H), 1.88 (p, J = 5.5 Hz, 1H), 1.58–1.49 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.19–1.10 (m, 2H). ESI-MS m / z: 680.3 [M+H] + 。
[0090] Compound S9: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.47–8.39 (m, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.89 (t, J = 0.7 Hz, 1H), 3.86 (dd, J = 9.1, 5.6 Hz, 2H), 3.69 (dd, J = 9.2, 5.6 Hz, 2H), 3.64 (s, 4H), 3.51–3.42 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.04 (s, 4H), 2.97 (s, 3H), 2.63–2.53 (m, 1H), 2.30 (s, 3H), 1.90–1.82 (m, 1H), 1.52–1.43 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.14–1.01 (m, 2H). ESI-MS m / z: 692.3 [M+H] + 。
[0091] Compound S10: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.42 (d, J = 0.9 Hz, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.16 (s, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.91 (t, J = 0.7 Hz, 1H), 4.00 (dd, J = 9.8, 4.9 Hz, 2H), 3.96–3.83 (m, 3H), 3.68 (dd, J = 9.1, 5.5 Hz, 2H), 3.60–3.39 (m, 3H), 3.39–3.26 (m, 5H), 2.97 (s, 3H), 2.63 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.57–1.50 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.17–1.10 (m, 2H). ESI-MS m / z: 667.2 [M+H] + 。
[0092] Compound S11: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.63 (d, J = 5.6 Hz, 1H), 8.41–8.27 (m, 2H), 8.13–8.01 (m, 2H), 7.53 (d, J = 5.6 Hz, 1H), 6.93–6.86 (m, 1H), 4.21 (p, J = 6.7 Hz, 1H), 4.01–3.88 (m, 4H), 3.71 (dd, J = 9.2, 5.6 Hz, 1H), 3.64 (s, 4H), 3.55–3.51 (m, 1H), 3.33 (dd, J = 6.2, 1.4 Hz, 2H), 3.04 (s, 4H), 2.95 (s, 3H), 2.96–2.80 (m, 1H), 2.30 (s, 3H), 1.38–1.19 (m, 9H). ESI-MS m / z: 616.3 [M+H] + 。
[0093] Compound S12: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.42 (d, J = 0.5 Hz, 1H), 8.38–8.27 (m, 2H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.92 (t, J = 0.7 Hz, 1H), 3.88 (dd, J = 9.1, 5.5 Hz, 2H), 3.73–3.57 (m, 6H), 3.50–3.44 (m, 1H), 3.35 (d, J = 6.0 Hz, 2H), 2.95 (s, 3H), 2.66–2.60 (m, 1H), 2.02–1.81 (m, 3H), 1.53–1.47 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.14–1.07 (m, 2H). ESI-MS m / z: 637.2 [M+H] + 。
[0094] Compound S13: 11H NMR (500 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.45–8.38 (m, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.92 (t, J = 0.7 Hz, 1H), 3.84 (dd, J = 9.1, 5.6 Hz, 2H), 3.71 (dd, J = 9.1, 5.5 Hz, 2H), 3.67 (s, 4H), 3.52–3.48 (m, 1H), 3.40–3.28 (m, 6H), 2.96 (s, 3H), 2.63–2.55 (m, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.53–1.48 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.15–1.09 (m, 2H). ESI-MS m / z: 727.2 [M+H] + 。
[0095] Compound S14: 1 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.45–8.38 (m, 2H), 8.31 (t, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.90 (t, J = 0.7 Hz, 1H), 3.84 (dd, J = 9.1, 5.5 Hz, 2H), 3.77–3.65 (m, 10H), 3.53–3.47 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.57–1.50 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.15–1.09 (m, 2H). ESI-MS m / z: 679.2 [M+H] + 。
[0096] Compound S15: 11H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.47–8.39 (m, 3H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.88–6.81 (m, 1H), 6.69 (t, J = 3.7 Hz, 1H), 3.85 (dd, J = 9.2, 5.6 Hz, 2H), 3.72–3.45 (m, 7H), 3.41–3.29 (m, 4H), 2.95 (s, 3H), 2.83–2.75 (m, 1H), 2.42 (dt, J = 6.7, 6.1 Hz, 6H), 1.88 (p, J = 5.5 Hz, 1H), 1.70 (p, J = 6.3 Hz, 2H), 1.55–1.43 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.16–1.10 (m, 2H). ESI-MS m / z: 724.3 [M+H] + 。
[0097] Compound S16: 1 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.45–8.37 (m, 2H), 8.31 (t, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.90–6.83 (m, 1H), 4.34 (p, J = 6.7 Hz, 1H), 3.95 (dd, J = 9.2, 6.9 Hz, 1H), 3.91–3.72 (m, 3H), 3.58–3.41 (m, 3H), 3.47–3.23 (m, 2H), 2.96 (s, 3H), 2.97–2.87 (m, 1H), 2.93–2.74 (m, 2H), 2.65 (p, J = 5.5 Hz, 1H), 2.40–2.27 (m, 3H), 1.55–1.49 (m, 2H), 1.38–1.15 (m, 9H), 1.21–1.06 (m, 2H). ESI-MS m / z: 680.3 [M+H] + 。
[0098] Compound S17: 11H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.47–8.39 (m, 2H), 8.31 (t, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.93 (t, J = 0.7 Hz, 1H), 3.88 (ddd, J = 15.4, 9.1, 5.4 Hz, 4H), 3.69 (ddd, J = 9.3, 5.3, 4.1 Hz, 4H), 3.49–3.42 (m, 1H), 3.36 (d, J = 6.0 Hz, 2H), 2.97 (s, 3H), 2.86 (p, J = 5.2 Hz, 1H), 2.73–2.56 (m, 4H), 2.60–2.45 (m, 2H), 2.47–2.32 (m, 4H), 2.24 (s, 3H), 1.52–1.47 (m, 2H), 1.25 (d, J = 6.5 Hz, 6H), 1.14–1.10 (m, 2H). ESI-MS m / z: 735.3 [M+H] + 。
[0099] Compound S18: 1 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 5.6 Hz, 1H), 8.29 (d, J = 0.5 Hz, 1H), 8.19 (s, 1H), 7.64 (d, J = 4.2 Hz, 1H), 7.54 (d, J = 5.6 Hz, 1H), 7.24 (d, J = 4.4 Hz, 1H), 6.90 (t, J = 0.7 Hz, 1H), 3.82–3.77 (m, 4H), 3.70 (dd, J = 9.1, 5.6 Hz, 2H), 3.69–3.54 (m, 6H), 3.60–3.46 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.97 (s, 3H), 2.63–2.58 (m, 1H), 2.38–2.34 (m, 1H), 2.25–2.21 (m, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.52–1.48 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.14–1.09 (m, 2H). ESI-MS m / z: 693.3 [M+H] + 。
[0100] Compound S19: 11H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.58 (d, J = 5.6 Hz, 1H), 8.30 (t, J = 0.5 Hz, 1H), 8.22 (s, 1H), 7.65–7.50 (m, 2H), 7.21 (d, J = 4.4 Hz, 1H), 6.88 (t, J = 0.7 Hz, 1H), 3.87–3.83 (m, 4H), 3.73 (ddd, J = 16.3, 9.1, 5.3 Hz, 4H), 3.64–3.40 (m, 5H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.86 (p, J = 5.2 Hz, 1H), 2.72–2.56 (m, 2H), 2.60–2.47 (m, 4H), 1.52–1.47 (m, 2H), 1.25 (d, J = 6.5 Hz, 6H), 1.14–1.09 (m, 2H). ESI-MS m / z: 722.3 [M+H] + 。
[0101] Compound S20: 1 1H NMR (500 MHz, DMSO-d6) δ 8.89 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.45–8.34 (m, 2H), 8.31 (d, J = 0.5 Hz, 1H), 8.17 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.89 (d, J = 0.5 Hz, 1H), 3.93 (ddd, J = 17.6, 9.0, 5.3 Hz, 4H), 3.69 (dd, J = 9.2, 5.6 Hz, 2H), 3.57 (dd, J = 9.0, 5.2 Hz, 2H), 3.35 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.82 (p, J = 5.1 Hz, 1H), 2.72–2.47 (m, 2H), 2.26 (s, 6H), 1.88 (p, J = 5.5 Hz, 1H), 1.52 (tdd, J = 8.7, 5.4, 0.6 Hz, 2H), 1.21–1.02 (m, 4H), 0.95–0.79 (m, 2H). ESI-MS m / z: 678.3 [M+H] + 。
[0102] Compound S21: 11H NMR (500 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 8.42 (d, J = 0.5 Hz, 1H), 8.35–8.27 (m, 2H), 8.11 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.88 (d, J = 0.5 Hz, 1H), 3.83 (dd, J = 9.1, 5.5 Hz, 2H), 3.71 (dd, J = 7.6, 5.9 Hz, 10H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.94 (dtd, J = 12.3, 6.6, 5.7 Hz, 1H), 2.63 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.77–1.45 (m, 4H), 1.30 (d, J = 6.6 Hz, 3H), 1.14 (tdd, J = 9.6, 5.6, 0.8 Hz, 2H), 0.78 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 693.3 [M+H] + 。
[0103] Compound S22: 1 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.68 (d, J = 5.6 Hz, 1H), 8.55 (s, 1H), 8.41–8.27 (m, 3H), 7.52 (d, J = 5.6 Hz, 1H), 6.85 (d, J = 0.5 Hz, 1H), 3.82 (ddd, J = 15.6, 9.2, 5.4 Hz, 4H), 3.76–3.52 (m, 8H), 3.35 (dd, J = 6.0, 5.4 Hz, 3H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.55–2.32 (m, 2H), 2.25 (dp, J = 6.8, 5.3 Hz, 1H), 2.19–1.91 (m, 4H), 1.87–1.70 (m, 2H), 1.29–1.13 (m, 2H), 1.11–0.95 (m, 2H). ESI-MS m / z: 669.3 [M+H] + 。
[0104] Compound S23: 11H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.68 (d, J = 5.6 Hz, 1H), 8.54 (s, 1H), 8.42 (d, J = 0.5 Hz, 1H), 8.34 (dd, J = 9.1, 0.5 Hz, 2H), 7.53 (d, J = 5.6 Hz, 1H), 6.86 (t, J = 0.7 Hz, 1H), 6.22 (t, J = 3.7 Hz, 1H), 3.90 (dd, J = 9.1, 5.6 Hz, 2H), 3.62–3.43 (m, 5H), 3.35 (d, J = 6.0 Hz, 2H), 2.97 (s, 3H), 2.62 (q, J = 5.5 Hz, 3H), 2.47 (p, J = 6.4 Hz, 1H), 2.26 (s, 6H), 1.30–1.13 (m, 8H), 1.12–0.96 (m, 2H). ESI-MS m / z: 632.3 [M+H] + 。
[0105] Compound S24: 1 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.65 (d, J = 5.6 Hz, 1H), 8.38 (s, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.08 (d, J = 0.5 Hz, 1H), 7.95 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.89 (d, J = 0.5 Hz, 1H), 4.06 (d, J = 3.8 Hz, 2H), 3.95–3.84 (m, 4H), 3.72–3.58 (m, 4H), 3.35 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.86–2.68 (m, 3H), 2.65 (t, J = 3.7 Hz, 1H), 2.55 (p, J = 5.7 Hz, 1H), 1.77–1.61 (m, 4H), 1.44–1.27 (m, 1H), 1.18–1.02 (m, 2H), 0.94–0.79 (m, 2H), 0.56–0.40 (m, 2H), 0.33–0.17 (m, 2H). ESI-MS m / z: 640.3 [M+H] + 。
[0106] Compound S25: 11H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.62 (d, J = 5.6 Hz, 1H), 8.47 (s, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.08 (d, J = 0.5 Hz, 1H), 7.92 (s, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.85 (t, J = 0.7 Hz, 1H), 4.07–3.89 (m, 8H), 3.70 (dd, J = 9.1, 5.6 Hz, 2H), 3.62–3.42 (m, 3H), 3.36 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.72–2.54 (m, 1H), 2.11–1.99 (m, 2H), 1.49–1.33 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H), 0.59–0.44 (m, 2H), 0.32–0.16 (m, 2H). ESI-MS m / z: 629.3 [M+H] + 。
[0107] Compound S26: 1 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.65 (d, J = 5.6 Hz, 1H), 8.46 (s, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.08 (d, J = 0.5 Hz, 1H), 7.96 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.84 (t, J = 0.7 Hz, 1H), 4.07–3.89 (m, 6H), 3.66 (dd, J = 9.0, 5.2 Hz, 2H), 3.64–3.45 (m, 7H), 3.35 (d, J = 6.0 Hz, 2H), 2.97 (s, 3H), 2.88–2.68 (m, 2H), 2.57–2.47 (m, 4H), 1.51–1.34 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H), 0.60–0.44 (m, 2H), 0.32–0.16 (m, 2H). ESI-MS m / z: 672.3 [M+H] + 。
[0108] Compound S27: 11H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 0.5 Hz, 1H), 8.65 (d, J = 5.6 Hz, 1H), 8.46 (s, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.08 (d, J = 0.5 Hz, 1H), 7.96 (d, J = 0.5 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.91 (dd, J = 1.0, 0.5 Hz, 1H), 4.03 (d, J = 3.8 Hz, 2H), 3.91–3.87 (m, 4H), 3.68 (dd, J = 9.2, 5.6 Hz, 2H), 3.64–3.45 (m, 3H), 3.35 (d, J = 6.1 Hz, 2H), 2.98 (s, 3H), 2.79 (p, J = 5.1 Hz, 1H), 2.63–2.55 (m, 1H), 2.26 (s, 6H), 1.50–1.34 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H), 0.60–0.44 (m, 2H), 0.32–0.16 (m, 2H). ESI-MS m / z: 630.3 [M+H] + 。
[0109] Compound S28: 1 1H NMR (500 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.86 (d, J = 0.5 Hz, 1H), 8.50 (d, J = 5.6 Hz, 1H), 8.30 (d, J = 0.8 Hz, 1H), 8.22 (s, 1H), 8.00–7.89 (m, 2H), 7.46–7.35 (m, 2H), 7.13 (d, J = 5.6 Hz, 1H), 6.83 (t, J = 0.7 Hz, 1H), 3.94 (dd, J = 9.1, 5.6 Hz, 2H), 3.64 (s, 4H), 3.63 (dd, J = 9.1, 5.6 Hz, 2H), 3.51–3.46 (m, 1H), 3.35 (d, J = 6.0 Hz, 2H), 3.04 (s, 4H), 2.96 (d, J = 3.2 Hz, 6H), 2.78–2.72 (m, 1H), 2.30 (s, 3H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 691.3 [M+H] + 。
[0110] Compound S29: 11H NMR (500 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.87 (d, J = 0.5 Hz, 1H), 8.50 (d, J = 5.6 Hz, 1H), 8.34–8.23 (m, 2H), 8.00–7.90 (m, 2H), 7.46–7.35 (m, 2H), 7.13 (d, J = 5.6 Hz, 1H), 6.94–6.87 (m, 1H), 4.04 (dd, J = 9.8, 4.8 Hz, 2H), 3.96–3.83 (m, 3H), 3.66 (ddd, J = 18.5, 9.5, 5.3 Hz, 4H), 3.49–3.44 (m, 1H), 3.40–3.26 (m, 5H), 2.96 (d, J = 5.4 Hz, 6H), 2.77–2.72 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 666.2 [M+H] + 。
[0111] Compound S30: 1 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.34–8.17 (m, 4H), 7.77–7.66 (m, 2H), 7.13 (d, J = 5.6 Hz, 1H), 6.90 (t, J = 0.7 Hz, 1H), 3.89 (dd, J = 9.1, 5.5 Hz, 2H), 3.68 (dd, J = 9.1, 5.6 Hz, 2H), 3.67 (s, 4H), 3.49 (pd, J = 6.5, 0.9 Hz, 1H), 3.40–3.28 (m, 6H), 2.95 (s, 3H), 2.78–2.70 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 701.2 [M+H] + 。
[0112] Compound S31: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.33–8.23 (m, 2H), 8.25–8.14 (m, 2H), 7.70–7.59 (m, 2H), 7.13 (d, J = 5.6 Hz, 1H), 6.93 (t, J = 0.7 Hz, 1H), 3.95 (dd, J = 9.0, 5.1 Hz, 2H), 3.90–3.74 (m, 4H), 3.70 (dd, J = 9.1, 5.6 Hz, 2H), 3.64–3.50 (m, 4H), 3.49–3.44 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.89–2.68 (m, 2H), 2.57–2.47 (m, 4H), 1.25 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 696.3 [M+H] + 。
[0113] Compound S32: 1 1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 0.5 Hz, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.33–8.23 (m, 2H), 8.21–8.10 (m, 2H), 7.83–7.72 (m, 2H), 7.13 (d, J = 5.6 Hz, 1H), 7.00 (t, J = 0.7 Hz, 1H), 3.83–3.79 (m, 4H), 3.72 (ddd, J = 9.0, 5.3, 1.0 Hz, 4H), 3.50 (pd, J = 6.6, 0.9 Hz, 1H), 3.37 (d, J = 6.0 Hz, 2H), 2.97 (s, 3H), 2.94–2.75 (m, 2H), 2.28 (s, 6H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 654.3 [M+H] + 。
[0114] Compound S33: 11H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.63 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.21 (ddd, J = 7.8, 2.2, 1.2 Hz, 1H), 8.06 (s, 1H), 7.92 (ddd, J = 7.8, 2.2, 1.2 Hz, 1H), 7.71 (t, J = 2.2 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 5.6 Hz, 1H), 6.92 (d, J = 0.5 Hz, 1H), 3.98 (dd, J = 9.0, 5.1 Hz, 2H), 3.87 (dd, J = 9.2, 5.6 Hz, 2H), 3.64 (ddd, J = 17.5, 9.1, 5.4 Hz, 4H), 3.35 (d, J = 6.1 Hz, 2H), 2.94 (s, 3H), 2.80 (p, J = 5.1 Hz, 1H), 2.63 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 2.49 (dp, J = 16.6, 5.6 Hz, 2H), 2.26 (s, 6H), 1.49 (tdd, J = 8.8, 5.5, 0.5 Hz, 2H), 1.18–0.82 (m, 6H). ESI-MS m / z: 688.3 [M+H] + 。
[0115] Compound S34: 1 1H NMR (500 MHz, DMSO-d6) δ 10.16 (s, 1H), 8.85 (d, J = 0.5 Hz, 1H), 8.63 (d, J = 5.6 Hz, 1H), 8.34–8.20 (m, 2H), 8.14 (s, 1H), 7.98–7.86 (m, 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.13 (d, J = 5.6 Hz, 1H), 6.84 (dd, J = 1.0, 0.5 Hz, 1H), 4.13 (dd, J = 9.9, 4.8 Hz, 2H), 3.98–3.82 (m, 3H), 3.63–3.38 (m, 5H), 3.30 (s, 3H), 2.62–2.39 (m, 7H), 1.26 (d, J = 6.5 Hz, 6H), 1.17–0.92 (m, 4H). ESI-MS m / z: 676.3 [M+H] + 。
[0116] Compound S35: 11H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J = 0.5 Hz, 1H), 8.60 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.15 (s, 1H), 7.52 (d, J = 5.6 Hz, 1H), 7.26–7.19 (m, 1H), 7.10–7.02 (m, 1H), 6.95 (t, J = 0.7 Hz, 1H), 6.72 (dd, J = 4.2, 1.5 Hz, 1H), 3.89 (dd, J = 9.1, 5.6 Hz, 2H), 3.72 (dd, J = 9.1, 5.6 Hz, 2H), 3.53–3.48 (m, 1H), 3.39–3.23 (m, 4H), 3.05 (s, 3H), 2.97 (s, 3H), 2.62 (q, J = 5.7 Hz, 3H), 2.36 (s, 6H), 1.84 (p, J = 5.5 Hz, 1H), 1.39–1.33 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H), 1.04–0.99 (m, 2H). ESI-MS m / z: 681.3 [M+H] + 。
[0117] Compound S36: 1 1H NMR (500 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.60 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.22 (s, 1H), 7.52 (d, J = 5.6 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1H), 7.04 (d, J = 4.2 Hz, 1H), 7.00–6.93 (m, 1H), 6.73 (dd, J = 4.2, 1.5 Hz, 1H), 4.24 (p, J = 6.7 Hz, 1H), 4.04–3.87 (m, 3H), 3.67 (dd, J = 9.2, 5.6 Hz, 1H), 3.63–3.45 (m, 3H), 3.33 (dd, J = 6.2, 2.4 Hz, 2H), 2.95 (s, 3H), 3.00–2.83 (m, 1H), 2.81 (p, J = 5.1 Hz, 1H), 2.26 (s, 6H), 1.84 (p, J = 5.5 Hz, 1H), 1.44 (d, J = 6.7 Hz, 3H), 1.25 (dd, J = 15.0, 6.5 Hz, 6H), 1.14–0.88 (m, 4H). ESI-MS m / z: 693.3 [M+H] + 。
[0118] Compound S37: 11H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.17 (s, 1H), 7.52 (d, J = 5.6 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.02 (d, J = 4.2 Hz, 1H), 6.90 (t, J = 0.7 Hz, 1H), 6.70 (dd, J = 4.2, 1.5 Hz, 1H), 3.83 (dd, J = 9.1, 5.5 Hz, 2H), 3.71 (dd, J = 9.2, 5.6 Hz, 2H), 3.62 (s, 4H), 3.54–3.49 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.66–2.60 (m, 1H), 2.58–2.36 (m, 4H), 2.26 (s, 3H), 1.84 (p, J = 5.5 Hz, 1H), 1.56 (t, J = 5.3 Hz, 4H), 1.26 (d, J = 6.5 Hz, 6H), 1.15–0.88 (m, 4H). ESI-MS m / z: 719.3 [M+H] + 。
[0119] Compound S38: 1 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 0.5 Hz, 1H), 8.61 (d, J = 5.6 Hz, 1H), 8.34–8.21 (m, 2H), 7.52 (d, J = 5.6 Hz, 1H), 7.36 (d, J = 1.5 Hz, 1H), 7.07 (d, J = 4.2 Hz, 1H), 7.02–6.94 (m, 1H), 6.76 (dd, J = 4.3, 1.5 Hz, 1H), 3.96 (dd, J = 9.0, 5.1 Hz, 2H), 3.82 (dd, J = 9.1, 5.5 Hz, 2H), 3.73 (dd, J = 9.2, 5.6 Hz, 2H), 3.66–3.46 (m, 7H), 3.36 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.91–2.69 (m, 2H), 2.57–2.47 (m, 4H), 1.84 (p, J = 5.5 Hz, 1H), 1.25 (d, J = 6.5 Hz, 6H), 1.16–0.90 (m, 4H). ESI-MS m / z: 721.3 [M+H] + 。
[0120] Compound S39: 11H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 5.6 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.22 (s, 1H), 7.52 (d, J = 5.6 Hz, 1H), 7.23 (d, J = 1.5 Hz, 1H), 7.02 (d, J = 4.2 Hz, 1H), 6.91 (t, J = 0.7 Hz, 1H), 6.72 (dd, J = 4.2, 1.5 Hz, 1H), 3.84 (dd, J = 9.1, 5.6 Hz, 2H), 3.75–3.63 (m, 10H), 3.52–3.48 (m, 1H), 3.36 (d, J = 6.1 Hz, 2H), 2.95 (s, 3H), 2.77 (dt, J = 11.5, 5.7 Hz, 1H), 1.84 (p, J = 5.5 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H), 1.15–0.89 (m, 4H). ESI-MS m / z: 678.2 [M+H] + 。
[0121] Compound S40: 1 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 5.6 Hz, 1H), 8.28 (d, J = 9.6 Hz, 3H), 8.12 (s, 1H), 7.54 (d, J = 5.6 Hz, 1H), 6.91 (t, J = 0.7 Hz, 1H), 3.90–3.85 (m, 4H), 3.75–3.59 (m, 5H), 3.35 (d, J = 6.0 Hz, 2H), 2.97 (s, 3H), 2.78 (p, J = 5.2 Hz, 1H), 2.63–2.57 (m, 1H), 2.27 (s, 6H), 1.88 (p, J = 5.5 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H), 1.22–0.99 (m, 4H). ESI-MS m / z: 680.3 [M+H] + 。
[0122] Compound S41: 11H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 5.6 Hz, 1H), 8.28 (d, J = 11.5 Hz, 3H), 8.12 (d, J = 0.5 Hz, 1H), 7.54 (d, J = 5.6 Hz, 1H), 6.90 (t, J = 0.7 Hz, 1H), 4.05–3.77 (m, 5H), 3.76–3.54 (m, 5H), 3.40–3.26 (m, 5H), 2.97 (s, 3H), 2.72–2.56 (m, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H), 1.22–0.99 (m, 4H). ESI-MS m / z: 667.2 [M+H] + .
[0123] Compound S42: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.57 (d, J = 5.6 Hz, 1H), 8.29 (d, J = 5.8 Hz, 3H), 8.06 (s, 1H), 7.54 (d, J = 5.6 Hz, 1H), 6.92–6.85 (m, 1H), 4.19 (p, J = 6.7 Hz, 1H), 3.96 (dd, J = 9.2, 6.8 Hz, 1H), 3.86 (dd, J = 9.2, 5.6 Hz, 2H), 3.73–3.55 (m, 2H), 3.44 (dd, J = 9.2, 5.6 Hz, 2H), 3.33 (dd, J = 6.2, 0.8 Hz, 2H), 3.24 (dd, J = 10.7, 6.2 Hz, 1H), 3.20 (s, 3H), 3.14 (dd, J = 10.8, 6.3 Hz, 1H), 2.95 (s, 3H), 2.96–2.79 (m, 1H), 2.31–2.25 (m, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.42 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.5 Hz, 6H), 1.23–0.99 (m, 4H). ESI-MS m / z: 695.3 [M+H] + .
[0124] Compound S43: 1H NMR(500MHz,DMSO-d6)δ8.86(d,J=0.5Hz,1H),8.59(d,J=5.6Hz,1H),8.34–8.2 2(m,3H),8.11(s,1H),7.54(d,J=5.6Hz,1H),6.91(t,J=0.7Hz,1H),3.83(dd,J =9.1,5.6Hz,2H),3.76–3.59(m,11H),3.35(d,J=6.1Hz,2H),2.96(s,3H),2.63 –2.57(m,1H),1.88(p,J=5.5Hz,1H),1.26(d,J=6.5Hz,6H),1.22–0.99(m,4H). ESI-MS m / z:679.2[M+H] + .
[0125] Compound S44: 1 H NMR(500MHz,DMSO-d6)δ9.08(s,1H),8.88(d,J=0.5Hz,1H),8.65–8.52(m,2H),8.41(s ,1H),8.28(d,J=0.6Hz,1H),7.52(d,J=5.6Hz,1H),6.92(t,J=0.7Hz,1H),4.00(d,J=11 .2Hz,2H),3.89(dd,J=9.2,5.6Hz,2H),3.79–3.63(m,4H),3.65–3.45(m,3H),3.35(d,J =6.1Hz,2H),2.97(s,3H),2.71–2.55(m,1H),2.44–2.32(m,2H),1.26(d,J=6.5Hz,6H). ESI-MS m / z:592.2[M+H] + .
[0126] Example 2: Synthesis of Compound S45
[0127]
[0128] The synthetic route and preparation process are as follows:
[0129]
[0130] Step 1: Preparation of intermediate tert-butyl (S)-3-fluoro-4-oxopiperidine-1-carboxylate (7)
[0131] At -20°C, add a solution of R(+)-alpha-methylbenzylamine trifluoroacetate (1.95mmol) in THF (10mL) to a solution of N-fluorobisbenzenesulfonamide (3.07g, 9.75mmol) and sodium bicarbonate (1.55g, 14.63mmol) in THF (20mL). After reacting at -20°C for 10 minutes, slowly add N-tert-butyloxycarbonyl-4-piperidone (3.88g, 19.50mmol), continue to react for 24 hours, add water (10mL) to quench the reaction, and extract with ether three times. Combine the organic phases, dry them over anhydrous sodium sulfate, filter, concentrate, and separate by column chromatography to obtain compound 7 (2.5g, 75%). ESI-MS m / z: 218.1[M+H] + .
[0132] Step 2: Preparation of intermediate tert-butyl (3S,4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate (8)
[0133] At 0°C, tetramethylammonium borohydride (491 mg, 5.52 mmol) was added to a solution of tert-butyl (S)-3-fluoro-4-oxopiperidine-1-carboxylate (7) (1.0 g, 4.60 mmol) in methanol (20 mL). The reaction was continued at 0°C for 4 hours until the reaction was complete. Saturated ammonium chloride was added to quench the reaction and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 8 (856 mg, 85%). ESI-MS m / z: 220.1 [M+H] + .
[0134] Step 3: Synthesis of intermediate tert-butyl (3S,4R)-3-fluoro-4-methoxypiperidine-1-carboxylate (9)
[0135] At 0°C, NaH (52 mg, 1.3 mmol, 60%) was added to a solution of tert-butyl (3S, 4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate (8) (219 mg, 1.0 mmol) in anhydrous THF (3 mL). After reacting for 1 hour, iodomethane (184 mg, 1.3 mmol) was added thereto. After the reaction was completed at 0°C for 1 hour, saturated ammonium chloride was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain compound 9 (210 mg, 90%). ESI-MS m / z: 234.1 [M+H] + .
[0136] Step 4: Synthesis of intermediate (3S,4R)-3-fluoro-4-methoxypiperidinium trifluoroacetate (10)
[0137] At room temperature, trifluoroacetic acid (380 μL, 5.0 mmol) was added to a DCM (2 mL) solution of tert-butyl (3S, 4R)-3-fluoro-4-methoxypiperidine-1-carboxylate (9) (233 mg, 1.0 mmol). The reaction was complete after 3 hours, and the compound 10 (172 mg, 75%) was obtained after distillation under reduced pressure. ESI-MS m / z: 134.1 [M+H]+.
[0138] Step 5: Preparation of intermediate 2-(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-amine (11)
[0139] Triethylamine (416 μL, 3.0 mmol) was added to a solution of (3S, 4R)-3-fluoro-4-methoxypiperidinium trifluoroacetate (10) (230 mg, 1.0 mmol) and 4-amino-2-chloropyrimidine (130 mg, 1.0 mmol) in isopropanol (5 mL). The reaction was completed after 4 hours at 90°C. After cooling to room temperature, the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain compound 11 (154 mg, 68%). ESI-MS m / z: 227.1 [M+H] + .
[0140] Step 6: N 7 -(2-(dimethylamino)ethyl)-N 3 -(2-((3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)-5-isopropyl-N 7 Synthesis of 8-(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl)isoquinoline-3,7-diamine (S45)
[0141] At 0℃, N 1 -(3-chloro-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-7-yl)-N 1 ,N 2 ,N 21,4-dioxane (5 mL) solution of 2-(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-amine (11) (226 mg, 1.0 mmol) was added with Brettphos Pd G3 (181 mg, 0.2 mmol) and cesium carbonate (975 mg, 3.0 mmol). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted with EA three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound S1 (321 mg, 49%). 1 H NMR (500MHz, DMSO-d6) δ8.91(d,J=0.5Hz,1H),8.32(d,J=0.5Hz,1H),8.15(d,J=5.6Hz,1H),7.90(s,1H),6.96(dd,J=1.0,0.5Hz,1H) ,6.27(d,J=5.6Hz,1H),4.66(ddd,J=4.0,3.3,1.7Hz,1H),4.50(ddd,J=4.0,3.3,1.7Hz,1H),4.14(p,J=6.7Hz,1H),4.07–3.89(m,2H) ,3.86–3.72(m,2H),3.77–3.51(m,3H),3.44–3.29(m,3H),3.24(s,3H),3.22–3.10(m,1H),3.05(s,3H),2.95(s,3H),2.96–2.83(m,1 H),2.81(dt,J=12.2,5.8Hz,1H),2.45(dt,J=12.1,5.8Hz,1H),2.36(s,6H),2.30–2.12(m,1H),1.89–1.77(m,1H),1.37–1.19(m,9H). ESI-MS m / z:657.4[M+H] + .
[0142] Compounds S46-S107 were prepared by referring to the method in Example 2.
[0143] Compound S46: 11H NMR (500 MHz, DMSO-d6) δ 8.84 (d, J = 0.5 Hz, 1H), 8.43 (d, J = 0.7 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 6.89–6.82 (m, 1H), 6.32–6.19 (m, 2H), 4.66–4.61 (m, 1H), 4.51–4.46 (m, 1H), 4.07–3.89 (m, 3H), 3.86–3.75 (m, 1H), 3.78–3.63 (m, 2H), 3.69–3.59 (m, 2H), 3.65–3.49 (m, 1H), 3.54–3.37 (m, 2H), 3.43–3.21 (m, 4H), 2.98–2.77 (m, 4H), 2.71 (dt, J = 12.9, 5.6 Hz, 1H), 2.55 (dt, J = 12.8, 5.5 Hz, 1H), 2.26 (s, 6H), 2.28–2.12 (m, 1H), 1.88–1.83 (m, 1H), 1.37–1.19 (m, 9H). ESI-MS m / z: 643.4 [M+H] + 。
[0144] Compound S47: 1 1H NMR (500 MHz, DMSO-d6) δ 8.93 (s, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.93 (s, 1H), 6.92 (dd, J = 1.0, 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.69 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.54 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 3.98 (ddd, J = 12.1, 7.9, 5.6 Hz, 1H), 3.94–3.45 (m, 8H), 3.51–3.31 (m, 4H), 3.26 (s, 3H), 3.17–3.03 (m, 2H), 2.97 (s, 3H), 2.75 (ddd, J = 12.1, 7.8, 5.8 Hz, 2H), 2.73–2.57 (m, 5H), 2.62–2.41 (m, 1H), 2.34 (s, 3H), 2.30–2.12 (m, 1H), 2.08 (ddd, J = 12.2, 8.0, 5.8 Hz, 2H), 1.93–1.87 (m, 1H), 1.75–1.48 (m, 4H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 724.4 [M+H] + 。
[0145] Compound S48:1 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.43 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.85 (s, 1H), 6.91–6.84 (m, 1H), 6.31–6.18 (m, 2H), 4.73 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.58 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.06–3.30 (m, 13H), 3.25 (s, 3H), 2.95 (s, 3H), 2.93–2.77 (m, 1H), 2.71 (dt, J = 12.8, 5.5 Hz, 1H), 2.55 (dt, J = 12.9, 5.5 Hz, 1H), 2.26 (s, 6H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.5, 7.9, 5.6, 3.6 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 629.3 [M+H] + 。
[0146] Compound S49: 1 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.90 (s, 1H), 7.00 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.05–3.37 (m, 11H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 3.05 (s, 3H), 2.96 (s, 3H), 2.76–2.54 (m, 2H), 2.40 (dt, J = 12.2, 5.8 Hz, 1H), 2.36 (s, 6H), 2.30–2.12 (m, 1H), 1.92 (dddd, J = 13.5, 8.0, 5.7, 3.7 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 643.4 [M+H] + 。
[0147] Compound S50: 11H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 0.5 Hz, 1H), 8.41 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.75 (s, 1H), 7.11–7.04 (m, 1H), 6.69 (t, J = 3.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.69 (ddd, J = 3.9, 3.3, 1.7 Hz, 1H), 4.54–4.50 (m, 1H), 3.98 (ddd, J = 12.1, 8.0, 5.6 Hz, 1H), 3.91–3.78 (m, 3H), 3.82–3.59 (m, 3H), 3.65–3.51 (m, 5H), 3.57–3.42 (m, 1H), 3.48–3.32 (m, 3H), 3.29–3.13 (m, 4H), 2.95 (s, 3H), 2.78 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 2.54–2.31 (m, 6H), 2.36–2.12 (m, 1H), 1.95–1.91 (m, 1H), 1.69–1.59 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 685.4 [M+H] + 。
[0148] Compound S51: 1 1H NMR (500 MHz, DMSO-d6) δ 8.81 (d, J = 0.4 Hz, 1H), 8.43 (d, J = 0.7 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.80 (s, 1H), 7.13–7.06 (m, 1H), 6.44 (t, J = 3.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.66 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 4.50 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.04–3.85 (m, 3H), 3.86–3.51 (m, 10H), 3.52–3.31 (m, 4H), 3.24 (s, 3H), 2.95 (s, 3H), 2.81–2.54 (m, 2H), 2.50–2.36 (m, 5H), 2.30–2.12 (m, 1H), 1.92–1.85 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 671.3 [M+H] + 。
[0149] Compound S52: 11H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 7.12–7.05 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.05–3.85 (m, 4H), 3.91–3.71 (m, 2H), 3.76–3.66 (m, 2H), 3.71–3.60 (m, 2H), 3.65–3.49 (m, 8H), 3.54–3.30 (m, 2H), 3.26 (s, 3H), 2.97 (s, 3H), 2.63 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.60–2.47 (m, 4H), 2.21–2.10 (m, 1H), 1.91–1.87 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 683.3 [M+H] + 。
[0150] Compound S53: 1 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 6.94–6.87 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.75 (ddd, J = 4.1, 3.4, 1.8 Hz, 1H), 4.59 (ddd, J = 4.1, 3.3, 1.7 Hz, 1H), 4.07–3.89 (m, 4H), 3.88–3.22 (m, 15H), 3.13 (td, J = 4.9, 0.5 Hz, 4H), 3.03–2.92 (m, 7H), 2.94–2.76 (m, 1H), 2.21–2.17 (m, 1H), 1.92–1.87 (m, 1H), 1.25 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 731.3 [M+H] + 。
[0151] Compound S54: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.03–6.96 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.4, 1.7 Hz, 1H), 4.05–3.89 (m, 2H), 3.87–3.67 (m, 3H), 3.72–3.52 (m, 9H), 3.57–3.22 (m, 8H), 2.95 (s, 3H), 2.93–2.77 (m, 1H), 2.44–2.12 (m, 3H), 1.92–1.87 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 654.3 [M+H] + 。
[0152] Compound S55: 1 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.93 (s, 1H), 6.97–6.90 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.59 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.07–3.30 (m, 17H), 3.26 (s, 3H), 2.97 (s, 3H), 2.84 (ddd, J = 12.2, 7.9, 5.7 Hz, 2H), 2.63 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.40 (ddd, J = 12.2, 8.0, 5.7 Hz, 2H), 2.31–2.12 (m, 4H), 2.04–1.83 (m, 2H), 1.79–1.35 (m, 4H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 695.4 [M+H] + 。
[0153] Compound S56: 11H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 6.93–6.86 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.57 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.06–3.37 (m, 14H), 3.36 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 3.00 (s, 3H), 2.80 (p, J = 5.1 Hz, 1H), 2.63 (ddd, J = 11.6, 6.0, 5.5 Hz, 1H), 2.27 (s, 6H), 1.98–1.78 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 641.3 [M+H] + 。
[0154] Compound S57: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.98 (s, 1H), 7.04–6.97 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.74 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.58 (ddd, J = 4.1, 3.4, 1.8 Hz, 1H), 4.07–3.73 (m, 4H), 3.77–3.39 (m, 12H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.97 (s, 3H), 2.63 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 2.21–2.16 (m, 2H), 1.93–1.88 (m, 1H), 1.70–1.60 (m, 4H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 668.3 [M+H] + 。
[0155] Compound S58: 11H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.22–7.15 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.70 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.55 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.88–3.71 (m, 4H), 3.75–3.64 (m, 8H), 3.70–3.48 (m, 4H), 3.49–3.31 (m, 4H), 3.25 (s, 3H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 1.92–1.87 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 640.3 [M+H] + 。
[0156] Compound S59: 1 1H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 6.69 (t, J = 3.7 Hz, 1H), 7.21–7.13 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.88–3.71 (m, 3H), 3.78–3.59 (m, 6H), 3.64–3.52 (m, 1H), 3.53 (d, J = 4.0 Hz, 1H), 3.49–3.29 (m, 3H), 3.29–3.13 (m, 4H), 2.96 (s, 3H), 2.81 (d, J = 5.2 Hz, 2H), 2.75–2.54 (m, 3H), 2.22–2.19 (m, 1H), 2.01–1.80 (m, 3H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 653.3 [M+H] + 。
[0157] Compound S60: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 7.02 (t, J = 0.7 Hz, 1H), 7.21–7.13 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.05–3.71 (m, 6H), 3.71–3.55 (m, 6H), 3.45 (pd, J = 6.5, 0.9 Hz, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.97 (s, 3H), 2.81 (tdd, J = 4.4, 2.7, 1.2 Hz, 2H), 2.72–2.54 (m, 2H), 2.21 (ddt, J = 13.2, 7.9, 5.8 Hz, 1H), 1.94–1.89 (m, 1H), 1.78–1.61 (m, 3H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 653.3 [M+H] + 。
[0158] Compound S61: 1 1H NMR (500 MHz, DMSO-d6) δ 8.83 (d, J = 0.5 Hz, 1H), 8.34 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.17 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.1, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.1, 3.3, 1.7 Hz, 1H), 3.98 (ddd, J = 12.0, 7.9, 5.6 Hz, 1H), 3.88–3.49 (m, 8H), 3.67 (s, 4H), 3.46–3.22 (m, 9H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.5, 8.1, 5.7, 3.7 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 688.3 [M+H] + 。
[0159] Compound S62: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 6.99 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.67 (ddd, J = 4.1, 3.3, 1.7 Hz, 1H), 4.51 (ddd, J = 4.1, 3.3, 1.7 Hz, 1H), 4.04–3.86 (m, 3H), 3.86–3.50 (m, 4H), 3.64 (s, 4H), 3.48–3.31 (m, 3H), 3.24 (s, 3H), 3.11–2.94 (m, 6H), 2.72–2.50 (m, 2H), 2.54–2.34 (m, 1H), 2.30–2.12 (m, 1H), 1.88 (dddd, J = 13.4, 7.9, 5.6, 3.6 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H), 1.05 (t, J = 7.2 Hz, 3H). ESI-MS m / z: 667.4 [M+H] + 。
[0160] Compound S63: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.4 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.94 (s, 1H), 7.02–6.95 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.69 (ddd, J = 3.9, 3.3, 1.7 Hz, 1H), 4.54 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.06–3.93 (m, 3H), 3.99–3.78 (m, 3H), 3.84–3.56 (m, 6H), 3.61–3.49 (m, 2H), 3.55–3.38 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.97 (s, 3H), 2.63 (ddd, J = 11.5, 6.0, 5.5 Hz, 1H), 2.38 (td, J = 7.4, 0.5 Hz, 2H), 2.21 (ddt, J = 13.2, 7.9, 5.8 Hz, 1H), 1.93–1.88 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 640.3 [M+H] + 。
[0161] Compound S64: 11H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.93 (s, 1H), 6.97–6.90 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.74 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.59 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 3.99 (ddd, J = 12.2, 8.0, 5.7 Hz, 1H), 3.94–3.72 (m, 5H), 3.76–3.36 (m, 9H), 3.35 (d, J = 6.1 Hz, 2H), 3.29–3.07 (m, 6H), 2.97 (s, 3H), 2.72–2.56 (m, 1H), 2.39–2.12 (m, 2H), 1.92–1.88 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 642.3 [M+H] + 。
[0162] Compound S65: 1 1H NMR (500 MHz, DMSO-d6) δ 8.83 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.98 (s, 1H), 7.20–7.13 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.69 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 4.53 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 3.99 (ddd, J = 12.2, 8.0, 5.7 Hz, 1H), 3.89–3.51 (m, 11H), 3.49–3.31 (m, 3H), 3.26 (s, 3H), 3.03 (s, 4H), 2.96 (s, 3H), 2.70–2.56 (m, 1H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.5, 8.1, 5.7, 3.7 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 656.3 [M+H] + 。
[0163] Compound S66: 11H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.20–7.13 (m, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.57 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.99 (ddd, J = 12.1, 7.5, 6.0 Hz, 1H), 3.88–3.42 (m, 11H), 3.47–3.31 (m, 3H), 3.25 (s, 3H), 2.96 (s, 3H), 2.99–2.89 (m, 1H), 2.94–2.80 (m, 2H), 2.75–2.54 (m, 3H), 1.98–1.76 (m, 2H), 1.61–1.42 (m, 3H), 1.48–1.32 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 667.4 [M+H] + 。
[0164] Compound S67: 1 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J = 0.5 Hz, 1H), 8.42 (t, J = 0.6 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.79 (s, 1H), 6.99–6.89 (m, 1H), 6.84 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.76 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.60 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.99 (ddd, J = 12.2, 8.0, 5.7 Hz, 1H), 3.88 (dd, J = 9.1, 5.6 Hz, 2H), 3.77 (ddd, J = 25.3, 11.2, 1.7 Hz, 1H), 3.71–3.60 (m, 2H), 3.66–3.54 (m, 2H), 3.60–3.47 (m, 2H), 3.54–3.32 (m, 7H), 3.34 (s, 1H), 3.25 (s, 3H), 2.96 (s, 3H), 2.81 (ddd, J = 11.6, 6.0, 5.5 Hz, 1H), 2.21 (ddt, J = 13.3, 8.0, 5.8 Hz, 1H), 1.91–1.87 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 616.3 [M+H] + 。
[0165] Compound S68: 1 H NMR(500MHz,DMSO-d6)δ8.89(d,J=0.5Hz,1H),8.31(d,J=0.6Hz,1H),8.15(d,J=5.6Hz,1 H),8.04(s,1H),6.95–6.88(m,1H),6.27(d,J=5.6Hz,1H),5.11(ddd,J=4.0,3.3,1.7Hz,1 H),4.60–4.49(m,1H),4.06–3.30(m,16H),3.26(s,3H),2.97(s,3H),2.84(s,3H),2.63(d dd,J=11.6,6.1,5.6Hz,1H),2.23–2.17(m,1H),1.92–1.87(m,1H),1.26(d,J=6.5Hz,6H). ESI-MS m / z:616.3[M+H] + .
[0166] Compound S69: 1 H NMR (500MHz, DMSO-d6) δ8.89(s,1H),8.32(d,J=0.5Hz,1H),8.15(d,J=5.6Hz,1H),7.90(s,1H),6.93(t,J=0.7Hz,1H),6.27(d ,J=5.6Hz,1H),4.72(ddd,J=4.0,3.3,1.7Hz,1H),4.56(ddd,J=4.0,3.3,1.7Hz,1H),4.04–3.71(m,4H),3.75–3.61(m,4H),3. 60–3.43(m,1H),3.48–3.34(m,1H),3.35(d,J=6.0Hz,2H),3.27(dt,J=12.2,6.3Hz,1H),3.26(s,3H),2.97(s,3H),2.83(s,3H ),2.72–2.46(m,2H),2.39(dt,J=12.2,6.4Hz,1H),2.23(s,6H),2.30–2.12(m,1H),2.00–1.63(m,3H),1.26(d,J=6.5Hz,6H). ESI-MS m / z:657.4[M+H] + .
[0167] Compound S70: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 6.90 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.74 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.59 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.06–3.91 (m, 2H), 3.94–3.84 (m, 3H), 3.89–3.69 (m, 2H), 3.75–3.61 (m, 2H), 3.68–3.50 (m, 4H), 3.56–3.43 (m, 2H), 3.48–3.35 (m, 2H), 3.35 (d, J = 6.0 Hz, 2H), 3.25 (s, 3H), 2.94 (s, 3H), 2.86–2.68 (m, 1H), 2.30–2.09 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 628.3 [M+H] + 。
[0168] Compound S71: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J = 0.5 Hz, 1H), 8.29 (t, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 6.92 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 5.11 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.95 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.07–3.71 (m, 4H), 3.75–3.64 (m, 2H), 3.70–3.54 (m, 4H), 3.61–3.48 (m, 2H), 3.54–3.39 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 2.97 (s, 3H), 2.62 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.29–2.11 (m, 1H), 2.02–1.84 (m, 3H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 598.3 [M+H] + 。
[0169] Compound S72: 11H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 7.27 (d, J = 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.07 (ddd, J = 12.1, 7.7, 6.0 Hz, 1H), 3.88–3.62 (m, 5H), 3.68–3.56 (m, 1H), 3.62 (s, 3H), 3.62–3.48 (m, 2H), 3.35 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.58–2.36 (m, 5H), 2.27 (s, 3H), 1.99–1.76 (m, 2H), 1.56 (t, J = 5.3 Hz, 4H), 1.16–1.00 (m, 2H), 0.93–0.77 (m, 2H). ESI-MS m / z: 679.4 [M+H] + 。
[0170] Compound S73: 1 1H NMR (500 MHz, DMSO-d6) δ 8.92 (s, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.94 (s, 1H), 7.00 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.68 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 4.52 (ddd, J = 4.0, 3.3, 1.8 Hz, 1H), 4.04–3.51 (m, 14H), 3.52–3.31 (m, 3H), 3.25 (s, 3H), 2.95 (s, 3H), 2.63 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.30–2.12 (m, 1H), 2.11–1.99 (m, 2H), 1.88 (dddd, J = 13.4, 8.0, 5.6, 3.6 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 640.3 [M+H] + 。
[0171] Compound S74: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.80 (s, 1H), 6.87 (d, J = 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.93 (p, J = 3.6 Hz, 1H), 4.83–4.67 (m, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.10 (dd, J = 10.0, 3.6 Hz, 1H), 4.07–3.89 (m, 2H), 3.91–3.74 (m, 4H), 3.79–3.68 (m, 2H), 3.74–3.49 (m, 3H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.96 (s, 3H), 2.94 (qt, J = 6.6, 5.6 Hz, 1H), 2.72–2.56 (m, 1H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.5, 7.9, 5.7, 3.6 Hz, 1H), 1.81–1.47 (m, 2H), 1.27 (d, J = 6.6 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 630.3 [M+H] + 。
[0172] Compound S75: 1 1H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.18 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.97 (ddd, J = 12.1, 8.0, 5.6 Hz, 1H), 3.88–3.49 (m, 7H), 3.67 (s, 4H), 3.46–3.30 (m, 3H), 3.26 (s, 3H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.43 (s, 1H), 2.36 (s, 2H), 2.29 (s, 1H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.5, 8.1, 5.7, 3.7 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 674.3 [M+H] + 。
[0173] Compound S76: 1 H NMR (500MHz, DMSO-d6) δ8.87(s,1H),8.31(d,J=0.5Hz,1H),8.15(d,J=5.6Hz,1H),7.73(s,1H),6.87(d,J=0 .5Hz,1H),6.27(d,J=5.6Hz,1H),4.72(ddd,J=4.0,3.3,1.7Hz,1H),4.56(ddd,J=4.0,3.3,1.7Hz,1H),4.17 –3.49(m,13H),3.35(d,J=6.1Hz,2H),3.26(s,3H),2.97(s,3H),2.94(qt,J=6.7,5.6Hz,1H),2.72–2.56(m, 1H), 2.30–2.12 (m, 1H), 1.93–1.85 (m, 1H), 1.81–1.47 (m, 2H), 1.27 (d, J = 6.6Hz, 3H), 0.78 (t, J = 7.4Hz, 3H). ESI-MS m / z:642.3[M+H] + .
[0174] Compound S77: 1 H NMR(500MHz,DMSO-d6)δ8.90(s,1H),8.32(d,J=0.5Hz,1H),8.15(d,J=5.6Hz,1H),7.91(s,1H),6.91(d,J=0.5Hz,1H),6.27 (d,J=5.6Hz,1H),4.72(ddd,J=4.0,3.3,1.7Hz,1H),4.56(ddd,J=4.0,3.3,1.7Hz,1H),4.03–3.42(m,12H),3.35(d,J=6.1H z,2H),3.26(s,3H),2.97(s,3H),2.92(tt,J=6.6,5.7Hz,1H),2.63(ddd,J=11.6,6.1,5.6Hz,1H),2.34–2.12(m,2H),1.91( dddd,J=13.5,7.9,5.6,3.6Hz,1H),1.80–1.47(m,2H),1.27(d,J=6.6Hz,3H),1.06(d,J=7.0Hz,3H),0.78(t,J=7.4Hz,3H). ESI-MS m / z:626.3[M+H] + .
[0175] Compound S78: 11H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.78 (s, 1H), 6.88 (d, J = 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.71 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.56 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 3.99 (ddd, J = 12.1, 8.0, 5.7 Hz, 1H), 3.89–3.65 (m, 5H), 3.65 (s, 4H), 3.71–3.57 (m, 1H), 3.63–3.49 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.96 (s, 3H), 2.89 (s, 4H), 2.63 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.52 (p, J = 5.7 Hz, 1H), 2.21 (ddt, J = 13.2, 7.9, 5.8 Hz, 1H), 1.93 (dddd, J = 13.4, 8.0, 5.6, 3.6 Hz, 1H), 1.46 (tdd, J = 10.1, 5.8, 0.8 Hz, 2H), 1.06 (tdd, J = 10.1, 5.8, 0.8 Hz, 2H). ESI-MS m / z: 650.3 [M+H] + 。
[0176] Compound S79: 11H NMR (500 MHz, DMSO-d6) δ 8.84 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.73 (s, 1H), 7.02 (d, J = 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.74 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.59 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.07–3.89 (m, 3H), 3.65 (s, 4H), 3.87–3.44 (m, 5H), 3.35 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 3.03 (s, 4H), 2.96 (s, 3H), 2.98–2.74 (m, 2H), 2.41 (hept, J = 6.5 Hz, 1H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.4, 8.0, 5.6, 3.6 Hz, 1H), 1.75–1.51 (m, 2H), 1.27 (d, J = 6.6 Hz, 3H), 1.08 (d, J = 6.5 Hz, 6H), 0.78 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 695.4 [M+H] + 。
[0177] Compound S80: 1 1H NMR (500 MHz, DMSO-d6) δ 8.85 (d, J = 0.5 Hz, 1H), 8.43 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.37 (s, 1H), 6.83 (d, J = 0.5 Hz, 1H), 6.32–6.18 (m, 2H), 4.72 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.56 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.02 (ddd, J = 12.1, 8.0, 5.7 Hz, 1H), 3.94–3.30 (m, 11H), 3.26 (s, 3H), 2.95 (s, 3H), 2.93–2.76 (m, 1H), 2.71 (dt, J = 12.8, 5.5 Hz, 1H), 2.67–2.47 (m, 2H), 2.26 (s, 6H), 2.28–2.12 (m, 1H), 1.92 (dddd, J = 13.4, 7.9, 5.6, 3.6 Hz, 1H), 1.18–1.02 (m, 2H), 0.95–0.80 (m, 2H). ESI-MS m / z: 627.3 [M+H] + 。
[0178] Compound S81:1 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 7.01 (d, J = 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.74 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 4.59 (ddd, J = 4.0, 3.3, 1.7 Hz, 1H), 3.99 (ddd, J = 12.0, 7.9, 5.6 Hz, 1H), 3.90 (dd, J = 9.1, 5.6 Hz, 2H), 3.78 (ddd, J = 25.1, 11.2, 1.7 Hz, 1H), 3.70–3.42 (m, 6H), 3.36 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 3.05 (s, 3H), 2.95 (s, 3H), 3.02–2.77 (m, 2H), 2.67 (dt, J = 12.1, 5.7 Hz, 1H), 2.41 (dt, J = 12.1, 5.8 Hz, 1H), 2.36 (s, 6H), 2.30–2.12 (m, 1H), 1.91 (dddd, J = 13.4, 7.9, 5.6, 3.6 Hz, 1H), 1.80–1.48 (m, 2H), 1.27 (d, J = 6.6 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 657.4 [M+H] + 。
[0179] Compound S82: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.03–6.96 (m, 1H), 5.03 (td, J = 3.4, 2.2 Hz, 1H), 4.87 (td, J = 3.4, 2.2 Hz, 1H), 4.00 (ddd, J = 12.1, 7.6, 6.0 Hz, 1H), 3.99–3.49 (m, 14H), 3.52–3.40 (m, 1H), 3.44–3.28 (m, 3H), 3.09 (p, J = 5.1 Hz, 1H), 2.89 (s, 3H), 2.59–2.41 (m, 5H), 1.96–1.74 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 686.4 [M+H] + 。
[0180] Compound S83:11 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.00 (t, J = 0.7 Hz, 1H), 5.04 (td, J = 3.3, 2.2 Hz, 1H), 4.89 (td, J = 3.4, 2.2 Hz, 1H), 4.08–3.82 (m, 2H), 3.88–3.67 (m, 3H), 3.74–3.56 (m, 10H), 3.49–3.37 (m, 1H), 3.40–3.28 (m, 3H), 2.89 (s, 3H), 2.50 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 1.96–1.76 (m, 2H), 1.40–1.22 (m, 10H). ESI-MS m / z: 671.4 [M+H] + 。
[0181] Compound S84: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.03–6.96 (m, 1H), 5.04 (td, J = 3.4, 2.2 Hz, 1H), 4.89 (td, J = 3.4, 2.2 Hz, 1H), 4.00 (ddd, J = 12.1, 7.6, 6.0 Hz, 1H), 3.99–3.45 (m, 14H), 3.49–3.37 (m, 1H), 3.40–3.28 (m, 3H), 2.89 (s, 3H), 2.50 (ddd, J = 11.7, 6.1, 5.6 Hz, 1H), 2.40–2.23 (m, 1H), 2.11–2.07 (m, 1H), 1.96–1.74 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 657.3 [M+H] + 。
[0182] Compound S85: 11H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 14.2 Hz, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 6.95 (t, J = 0.7 Hz, 1H), 6.36 (t, J = 3.7 Hz, 1H), 5.03 (td, J = 3.4, 2.2 Hz, 1H), 4.87 (td, J = 3.4, 2.2 Hz, 1H), 4.08–3.94 (m, 1H), 3.99–3.81 (m, 1H), 3.87–3.50 (m, 11H), 3.49–3.37 (m, 1H), 3.24 (td, J = 6.3, 3.7 Hz, 2H), 2.89 (s, 3H), 2.59–2.31 (m, 8H), 1.96–1.78 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 674.4 [M+H] + 。
[0183] Compound S86: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.04–6.97 (m, 1H), 5.04 (td, J = 3.4, 2.2 Hz, 1H), 4.89 (td, J = 3.4, 2.2 Hz, 1H), 4.08–3.94 (m, 1H), 3.99–3.81 (m, 1H), 3.87–3.69 (m, 3H), 3.74–3.56 (m, 4H), 3.49–3.40 (m, 1H), 3.44–3.22 (m, 6H), 2.89 (s, 3H), 2.75 (t, J = 5.8 Hz, 2H), 2.57–2.42 (m, 1H), 2.36 (s, 6H), 1.96–1.76 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 646.4 [M+H] + 。
[0184] Compound S87: 11H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.02–6.95 (m, 1H), 5.84 (s, 1H), 5.01–4.89 (m, 1H), 4.08–3.78 (m, 4H), 3.78–3.56 (m, 3H), 3.52–3.29 (m, 4H), 3.29–3.16 (m, 4H), 3.00–2.86 (m, 2H), 2.71–2.58 (m, 1H), 2.50–2.28 (m, 8H), 1.96–1.74 (m, 2H), 1.32–1.19 (m, 9H). ESI-MS m / z: 657.4 [M+H] + 。
[0185] Compound S88: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.00 (t, J = 0.7 Hz, 1H), 5.04 (td, J = 3.3, 2.2 Hz, 1H), 4.89 (td, J = 3.4, 2.2 Hz, 1H), 4.08–3.82 (m, 2H), 3.88–3.67 (m, 3H), 3.74–3.56 (m, 10H), 3.49–3.37 (m, 1H), 3.40–3.28 (m, 3H), 2.89 (s, 3H), 2.50 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 1.96–1.76 (m, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 643.3 [M+H] + 。
[0186] Compound S89: 11H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 14.2 Hz, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 6.99 (d, J = 0.5 Hz, 1H), 6.14 (t, J = 3.7 Hz, 1H), 5.04 (td, J = 3.4, 2.2 Hz, 1H) 4.00 (ddd, J = 12.2, 7.6, 6.0 Hz, 1H), 3.99–3.79 (m, 3H), 3.78–3.63 (m, 4H), 3.56–3.38 (m, 2H), 3.44–3.23 (m, 3H), 2.89 (s, 3H), 2.82–2.67 (m, 1H), 2.64 (t, J = 5.5 Hz, 2H), 2.26 (s, 6H), 1.96–1.74 (m, 2H), 1.53 (tdd, J = 10.1, 5.8, 0.8 Hz, 2H), 1.24 (d, J = 6.7 Hz, 3H), 1.14 (tdd, J = 10.1, 5.8, 0.9 Hz, 2H). ESI-MS m / z: 644.4 [M+H] + 。
[0187] Compound S90: 1 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.31 (d, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.87 (s, 1H), 6.93 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.27 (d, J = 7.2 Hz, 1H), 4.07–3.24 (m, 17H), 3.00–2.80 (m, 4H), 2.63 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 2.26 (s, 6H), 2.13 (dddd, J = 13.1, 7.9, 6.4, 5.6 Hz, 1H), 1.81 (dddd, J = 13.2, 8.1, 5.7, 4.1 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 627.3 [M+H] + 。
[0188] Compound S91: 11H NMR (500 MHz, DMSO-d6) δ 8.85 (d, J = 0.5 Hz, 1H), 8.31 (t, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.10 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 5.12–5.07 (m, 1H), 4.27 (d, J = 7.2 Hz, 1H), 4.10–3.94 (m, 3H), 3.93 (dd, J = 9.1, 5.6 Hz, 2H), 3.90–3.76 (m, 1H), 3.81–3.68 (m, 1H), 3.71 (s, 1H), 3.71–3.41 (m, 8H), 3.35 (d, J = 6.0 Hz, 2H), 2.95 (s, 3H), 2.93–2.77 (m, 1H), 2.45–2.30 (m, 2H), 2.13 (dddd, J = 13.2, 8.1, 6.5, 5.7 Hz, 1H), 1.87 (dddd, J = 13.4, 7.9, 5.6, 4.1 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 626.3 [M+H] + 。
[0189] Compound S92: 1 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 0.5 Hz, 1H), 8.31 (t, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.93 (s, 1H), 7.12 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.27 (d, J = 7.2 Hz, 1H), 4.00 (ddd, J = 12.2, 8.0, 5.6 Hz, 1H), 3.92–3.36 (m, 18H), 3.35 (d, J = 6.1 Hz, 2H), 2.94 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.15–2.11 (m, 1H), 1.84–1.79 (m, 1H), 1.70–1.60 (m, 4H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 654.3 [M+H] + 。
[0190] Compound S93: 11H NMR (500 MHz, DMSO-d6) δ 8.86 (s, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.89 (s, 1H), 6.91 (dd, J = 1.0, 0.5 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.27 (d, J = 7.2 Hz, 1H), 3.99 (ddd, J = 12.2, 7.9, 5.6 Hz, 1H), 3.90–3.77 (m, 3H), 3.83–3.63 (m, 12H), 3.69–3.58 (m, 1H), 3.63–3.49 (m, 1H), 3.47 (ddd, J = 13.0, 6.5, 0.9 Hz, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.96 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.14–2.10 (m, 1H), 1.86–1.83 (m, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 626.3 [M+H] + 。
[0191] Compound S94: 1 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 0.5 Hz, 1H), 8.31 (t, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.09 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.27 (d, J = 7.2 Hz, 1H), 3.98 (ddd, J = 12.1, 7.9, 5.6 Hz, 1H), 3.92–3.71 (m, 6H), 3.71 (d, J = 2.8 Hz, 1H), 3.69 (d, J = 3.6 Hz, 1H), 3.71–3.47 (m, 9H), 3.45 (dtd, J = 13.0, 6.5, 5.5 Hz, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.97 (s, 3H), 2.63 (ddd, J = 11.6, 6.1, 5.6 Hz, 1H), 2.53–2.36 (m, 1H), 2.25 (dp, J = 6.9, 5.3 Hz, 1H), 2.22–2.04 (m, 1H), 1.85 (dddd, J = 13.1, 7.9, 5.6, 4.1 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 640.3 [M+H] + 。
[0192] Compound S95: 11H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 0.5 Hz, 1H), 8.32 (d, J = 0.5 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 7.92 (s, 1H), 6.93 (t, J = 0.7 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.27 (d, J = 7.2 Hz, 1H), 4.05–3.18 (m, 15H), 2.97 (s, 3H), 2.80 (s, 3H), 2.72–2.47 (m, 2H), 2.23 (s, 6H), 2.30–2.04 (m, 2H), 1.92–1.75 (m, 2H), 1.70 (dq, J = 12.8, 6.3 Hz, 1H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 643.4 [M+H] + 。
[0193] Compound S96: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 6.99 (t, J = 0.7 Hz, 1H), 4.05 (ddd, J = 12.0, 7.9, 5.7 Hz, 2H), 3.83–3.46 (m, 16H), 3.35 (d, J = 6.1 Hz, 2H), 2.89 (s, 3H), 2.57–2.42 (m, 1H), 2.31 (dp, J = 6.9, 6.0 Hz, 1H), 2.11 (dp, J = 6.9, 5.3 Hz, 1H), 1.99 (ddt, J = 13.6, 8.0, 5.7 Hz, 2H), 1.85 (ddt, J = 13.4, 7.9, 5.6 Hz, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 639.4 [M+H] + 。
[0194] Compound S97: 11H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 7.00 (t, J = 0.7 Hz, 1H), 4.05 (ddd, J = 12.0, 7.9, 5.7 Hz, 2H), 3.82–3.58 (m, 16H), 3.35 (d, J = 6.1 Hz, 2H), 2.89 (s, 3H), 2.50 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 1.99 (ddt, J = 13.6, 8.0, 5.6 Hz, 2H), 1.85 (ddt, J = 13.4, 7.9, 5.6 Hz, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 625.3 [M+H] + 。
[0195] Compound S98: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 7.00 (t, J = 0.7 Hz, 1H), 4.05 (ddd, J = 12.0, 7.9, 5.7 Hz, 2H), 3.82–3.58 (m, 8H), 3.39–3.22 (m, 4H), 3.05 (s, 3H), 2.89 (s, 3H), 2.75 (t, J = 5.7 Hz, 2H), 2.50 (ddd, J = 11.6, 6.1, 5.5 Hz, 1H), 2.36 (s, 6H), 1.99 (ddt, J = 13.5, 8.0, 5.6 Hz, 2H), 1.85 (ddt, J = 13.4, 7.9, 5.6 Hz, 2H), 1.26 (d, J = 6.5 Hz, 6H). ESI-MS m / z: 628.4 [M+H] + 。
[0196] Compound S99: 11H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.05 (d, J = 0.5 Hz, 1H), 5.82 (s, 1H), 5.06–4.90 (m, 1H), 4.00 (ddd, J = 12.2, 7.6, 6.0 Hz, 1H), 3.89 (dddd, J = 25.3, 5.7, 4.0, 3.3 Hz, 1H), 3.80–3.63 (m, 3H), 3.65 (s, 4H), 3.68–3.56 (m, 2H), 3.56–3.40 (m, 2H), 3.44–3.29 (m, 1H), 3.02 (s, 4H), 2.54–2.36 (m, 6H), 2.23 (s, 3H), 1.98–1.74 (m, 2H), 1.52 (tdd, J = 10.1, 5.8, 0.9 Hz, 2H), 1.14 (tdd, J = 10.1, 5.8, 1.0 Hz, 2H). ESI-MS m / z: 653.4 [M+H] + 。
[0197] Compound S100: 1 1H NMR (500 MHz, DMSO-d6) δ 8.53 (d, J = 0.5 Hz, 1H), 8.33–8.22 (m, 2H), 8.12 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.04 (d, J = 0.5 Hz, 1H), 5.05–4.97 (m, 1H), 4.08–3.92 (m, 1H), 3.98–3.79 (m, 3H), 3.82–3.69 (m, 4H), 3.75–3.59 (m, 3H), 3.56–3.38 (m, 2H), 3.44–3.28 (m, 3H), 3.14 (p, J = 5.2 Hz, 1H), 2.89 (s, 3H), 2.50 (ddd, J = 11.7, 6.1, 5.5 Hz, 1H), 2.23 (s, 6H), 1.96–1.74 (m, 2H), 1.53 (tdd, J = 10.0, 5.8, 0.8 Hz, 2H), 1.14 (tdd, J = 10.1, 5.8, 0.9 Hz, 2H). ESI-MS m / z: 642.3 [M+H] + 。
[0198] Compound S101: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.5 Hz, 1H), 8.40 (d, J = 0.5 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 6.89 (t, J = 0.7 Hz, 1H), 6.33–6.22 (m, 2H), 5.11 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.95 (ddd, J = 4.1, 3.3, 1.8 Hz, 1H), 4.06–3.90 (m, 2H), 3.96–3.81 (m, 1H), 3.86–3.75 (m, 1H), 3.77–3.49 (m, 4H), 3.49–3.34 (m, 1H), 3.41–3.23 (m, 2H), 3.24 (s, 3H), 2.98–2.79 (m, 6H), 2.20 (ddt, J = 13.8, 8.1, 5.8 Hz, 1H), 1.88–1.81 (m, 1H), 1.34–1.19 (m, 9H). ESI-MS m / z: 586.3 [M+H] + 。
[0199] Compound S102: 1 1H NMR (500 MHz, DMSO-d6) δ 8.89 (s, 1H), 8.40 (s, 1H), 8.15 (d, J = 5.8 Hz, 1H), 7.72 (s, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.39 (q, J = 4.5 Hz, 1H), 6.27 (d, J = 5.5 Hz, 1H), 4.73 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 4.64 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 3.99 (ddd, J = 12.2, 7.9, 5.8 Hz, 1H), 3.88 (dd, J = 9.0, 5.6 Hz, 2H), 3.78 (ddd, J = 25.2, 11.1, 1.7 Hz, 1H), 3.65–3.49 (m, 4H), 3.44–3.39 (m, 1H), 3.35 (d, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.97 (s, 3H), 2.87 (d, J = 4.5 Hz, 3H), 2.62 (p, J = 5.8 Hz, 1H), 1.97–1.80 (m, 2H), 1.26 (d, J = 6.4 Hz, 6H). ESI-MS m / z: 572.3 [M+H] + 。
[0200] Compound S103: 11H NMR (500 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.41 (d, J = 0.9 Hz, 1H), 8.15 (d, J = 5.8 Hz, 1H), 7.90 (s, 1H), 6.93 (d, J = 1.2 Hz, 1H), 6.27 (d, J = 5.5 Hz, 1H), 5.83 (d, J = 9.4 Hz, 1H), 4.66–4.61 (m, 1H), 4.05–3.92 (m, 3H), 3.82–3.70 (m, 2H), 3.69–3.54 (m, 3H), 3.49–3.44 (m, 1H), 3.42–3.27 (m, 2H), 3.24 (s, 3H), 2.95 (s, 3H), 2.84 (h, J = 6.4 Hz, 1H), 2.67 (dp, J = 9.4, 5.7 Hz, 1H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.89–1.76 (m, 1H), 1.27 (dd, J = 14.5, 6.6 Hz, 9H), 0.63–0.54 (m, 2H), 0.55–0.45 (m, 2H). ESI-MS m / z: 612.3 [M+H] + 。
[0201] Compound S104: 1 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 0.6 Hz, 1H), 8.29 (s, 1H), 8.15 (d, J = 5.8 Hz, 1H), 7.91 (s, 1H), 6.94 (d, J = 1.2 Hz, 1H), 6.27 (d, J = 5.5 Hz, 1H), 4.75–4.70 (m, 1H), 4.66–4.60 (m, 1H), 3.99 (ddd, J = 12.2, 7.9, 5.8 Hz, 1H), 3.88 (dd, J = 9.2, 5.5 Hz, 2H), 3.78 (ddd, J = 25.2, 11.3, 1.7 Hz, 1H), 3.71–3.49 (m, 5H), 3.45–3.36 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.25 (s, 3H), 2.95 (s, 3H), 2.71 (s, 5H), 2.62–2.58 (m, 1H), 1.97–1.80 (m, 2H), 1.26 (d, J = 6.4 Hz, 6H). ESI-MS m / z: 586.3 [M+H] + 。
[0202] Compound S105: 11H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J = 0.6 Hz, 1H), 8.43 (s, 1H), 8.15 (d, J = 5.8 Hz, 1H), 7.79 (s, 1H), 6.86 (d, J = 1.3 Hz, 1H), 6.47 (d, J = 9.4 Hz, 1H), 6.27 (d, J = 5.8 Hz, 1H), 4.74–4.68 (m, 1H), 4.65–4.59 (m, 1H), 4.19–4.15 (m, 1H), 3.99 (ddd, J = 12.2, 8.1, 5.8 Hz, 1H), 3.93–3.76 (m, 4H), 3.79–3.72 (m, 1H), 3.76–3.55 (m, 4H), 3.59–3.49 (m, 2H), 3.45–3.41 (m, 1H), 3.35 (d, J = 6.0 Hz, 2H), 3.25 (s, 3H), 2.97 (s, 3H), 2.63–2.59 (m, 1H), 2.30–2.13 (m, 3H), 1.91–1.85 (m, 1H), 1.26 (dd, J = 25.1, 6.5 Hz, 6H). ESI-MS m / z: 628.3 [M+H] + 。
[0203] Compound S106: 1 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.43 (s, 1H), 8.15 (d, J = 5.8 Hz, 1H), 7.89 (s, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.30–6.21 (m, 2H), 5.08 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 5.01–4.96 (m, 1H), 4.03–3.92 (m, 2H), 3.86 (p, J = 6.6 Hz, 1H), 3.82–3.69 (m, 2H), 3.68–3.36 (m, 5H), 3.40–3.26 (m, 2H), 3.24 (s, 3H), 2.94 (s, 3H), 2.93–2.83 (m, 1H), 2.21–2.17 (m, 1H), 1.88–1.85 (m, 1H), 1.31–1.21 (m, 12H). ESI-MS m / z: 600.3 [M+H] + 。
[0204] Compound S107: 1H NMR (500MHz, DMSO-d6) δ8.89(d,J=0.6Hz,1H),8.39(s,1H),8.15(d,J=5.8Hz,1H),7.72(s,1H),6.86(d,J=1.3 Hz,1H),6.30–6.20(m,2H),5.08(ddd,J=4.1,3.2,1.7Hz,1H),5.01–4.96(m,1H),3.99(ddd,J=12.0,7.9,5.5H z,1H),3.88(dd,J=9.2,5.5Hz,2H),3.77(ddd,J=25.2,11.2,1.6Hz,1H),3.64–3.37(m,7H),3.35(d,J=6.0Hz, 2H),3.22(s,3H),2.97(s,3H),2.62(p,J=5.8Hz,1H),2.20–2.16(m,1H),1.87–1.82(m,1H),1.31–1.23(m,9H). ESI-MS m / z:586.3[M+H] + .
[0205] Example 3: Synthesis of Compound S108
[0206]
[0207] The synthetic route and preparation process are as follows:
[0208]
[0209] Step 1: Synthesis of 6-chloro-3-iodo-1-isopropyl-1H-pyrrolo[3,2-c]pyridine (12)
[0210] At 0°C, NaH (52 mg, 1.3 mmol, 60%) was added to a solution of 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine (278 mg, 1.0 mmol) in anhydrous THF (3 mL). After reacting for 1 hour, isopropyl bromide (156 mg, 1.3 mmol) was added thereto. After the reaction was completed at 0°C for 1 hour, saturated ammonium chloride was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain compound 12 (272 mg, 85%). ESI-MS m / z: 322.0 [M+H] + .
[0211] Step 2: Preparation of intermediate 6-chloro-1-isopropyl-3-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrrolo[3,2-c]pyridine (13)
[0212] To a DMF (2 mL) solution of 6-chloro-3-iodo-1-isopropyl-1H-pyrrolo[3,2-c]pyridine (12) (321 mg, 1.0 mmol) and (2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidine (163 mg, 1.0 mmol), CuI (190 mg, 1.0 mmol), potassium carbonate (415 mg, 3.0 mmol) and L-proline (115 mg, 1.0 mmol) were added. The reaction was completed after 4 hours at 100°C. After cooling to room temperature, the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain compound 11 (231 mg, 65%). ESI-MS m / z: 356.1 [M+H] + .
[0213] Step 3: Synthesis of N-(2-((3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)-1-isopropyl-3-((2R,3S)-2-methyl-3-(methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine (S108)
[0214] At 0°C, Brettphos Pd G3 (181 mg, 0.2 mmol) and cesium carbonate (975 mg, 3.0 mmol) were added to a solution of 6-chloro-1-isopropyl-3-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)-1H-pyrrolo[3,2-c]pyridine (13) (356 mg, 1.0 mmol) and 2-(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-amine (11) (226 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The reaction was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound S1 (300 mg, 55%). 1H NMR (500MHz, DMSO-d6) δ8.76(s,1H),8.51(d,J=1.0Hz,1H),8.16(d,J=5.5Hz,1H),6.84(s,1H),6.68(s,1H),6.28(d,J= 5.8Hz,1H),5.11–5.05(m,1H),5.01–4.96(m,1H),4.62(hept,J=6.3Hz,1H),4.23(p,J=6.7Hz,1H),4.01–3.86(m,2H),3. 82–3.70(m,2H),3.68–3.53(m,3H),3.39–3.27(m,2H),3.26(s,3H),2.94(s,3H),2.77(dq,J=12.7,6.4Hz,1H),2.20(ddt ,J=13.7,8.1,5.8Hz,1H),1.93(dddd,J=13.5,8.1,5.7,3.6Hz,1H),1.48(dd,J=25.0,6.4Hz,5H),1.37(d,J=6.6Hz,3H). ESI-MS m / z:546.3[M+H] + .
[0215] Compounds S109-S119 were prepared by referring to the method in Example 3.
[0216] Compound S109: 1 H NMR (500MHz, DMSO-d6) δ8.52(d,J=1.0Hz,1H),8.22(s,1H),8.15(d,J=5.5Hz,1H),6.85(s,1H),6.69(d,J=0.6H z,1H),6.28(d,J=5.5Hz,1H),4.74–4.69(m,1H),4.51–4.47(m,1H),4.03–3.89(m,3H),3.82–3.70(m,2H),3.68 –3.53(m,3H),3.39–3.27(m,2H),3.26(s,3H),2.94(s,3H),2.84–2.74(m,1H),2.02–1.92(m,1H),1.96–1.88(m ,1H),1.91–1.80(m,1H),1.70–1.65(m,1H),1.40(d,J=6.6Hz,3H),1.29(d,J=6.4Hz,3H),0.87(t,J=7.4Hz,3H). ESI-MS m / z:560.3[M+H] + .
[0217] Compound S110: 11H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 0.9 Hz, 1H), 8.18–8.13 (m, 2H), 6.82 (s, 1H), 6.69 (d, J = 0.6 Hz, 1H), 6.28 (d, J = 5.5 Hz, 1H), 5.08 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 5.01–4.96 (m, 1H), 4.25 (p, J = 5.5 Hz, 1H), 4.01–3.89 (m, 3H), 3.87–3.73 (m, 3H), 3.69–3.61 (m, 1H), 3.64–3.53 (m, 1H), 3.39–3.28 (m, 2H), 3.26 (s, 3H), 2.94 (s, 3H), 2.84–2.74 (m, 1H), 2.08–2.02 (m, 1H), 1.95–1.74 (m, 6H), 1.63–1.51 (m, 2H), 1.38 (d, J = 6.6 Hz, 3H). ESI-MS m / z: 572.3 [M+H] + 。
[0218] Compound S111: 1 1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 0.9 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 7.62 (s, 1H), 7.04 (s, 1H), 6.70 (d, J = 0.6 Hz, 1H), 6.28 (d, J = 5.8 Hz, 1H), 5.02–4.89 (m, 2H), 4.02–3.90 (m, 3H), 3.86–3.69 (m, 3H), 3.67–3.60 (m, 1H), 3.64–3.54 (m, 1H), 3.33 (dd, J = 6.3, 4.0 Hz, 2H), 3.26 (s, 3H), 2.94 (s, 3H), 2.81–2.76 (m, 1H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.89–1.84 (m, 1H), 1.39 (dd, J = 10.9, 6.4 Hz, 6H). ESI-MS m / z: 600.2 [M+H] + 。
[0219] Compound S112: 11H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 0.9 Hz, 1H), 8.26 (s, 1H), 8.15 (d, J = 5.5 Hz, 1H), 6.87 (d, J = 0.6 Hz, 1H), 6.69 (s, 1H), 6.28 (d, J = 5.5 Hz, 1H), 5.11–5.05 (m, 1H), 4.61–4.54 (m, 1H), 4.01–3.91 (m, 2H), 3.87–3.56 (m, 7H), 3.35 (d, J = 6.2 Hz, 2H), 3.27 (s, 3H), 2.94 (s, 3H), 2.78 (hept, J = 5.7 Hz, 1H), 2.20–2.16 (m, 1H), 1.90–1.85 (m, 1H), 1.47 (d, J = 6.4 Hz, 6H). ESI-MS m / z: 532.2 [M+H] + 。
[0220] Compound S113: 1 1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 0.9 Hz, 1H), 8.27 (s, 1H), 8.15 (d, J = 5.5 Hz, 1H), 6.79 (s, 1H), 6.69 (d, J = 0.6 Hz, 1H), 6.28 (d, J = 5.5 Hz, 1H), 5.11–5.05 (m, 1H), 5.01–4.96 (m, 1H), 4.41 (qt, J = 6.6, 5.4 Hz, 1H), 3.97 (ddd, J = 12.2, 8.0, 5.7 Hz, 1H), 3.87–3.55 (m, 7H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.96 (s, 3H), 2.84–2.79 (m, 1H), 2.20–2.14 (m, 1H), 2.01–1.85 (m, 2H), 1.75–1.70 (m, 1H), 1.28 (d, J = 6.4 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 546.3 [M+H] + 。
[0221] Compound S114: 11H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 0.9 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 8.09 (s, 1H), 6.78 (s, 1H), 6.66 (d, J = 0.6 Hz, 1H), 6.28 (d, J = 5.5 Hz, 1H), 5.11–5.05 (m, 1H), 5.01–4.96 (m, 1H), 4.10 (dd, J = 12.9, 3.7 Hz, 1H), 4.03–3.93 (m, 2H), 3.85 (dd, J = 9.2, 5.6 Hz, 1H), 3.81–3.55 (m, 6H), 3.35 (d, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.96 (s, 3H), 2.60 (dt, J = 11.5, 5.8 Hz, 1H), 2.20 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.91–1.86 (m, 1H), 1.36–1.29 (m, 1H), 0.60–0.46 (m, 4H). ESI-MS m / z: 544.2 [M+H] + 。
[0222] Compound S115: 1 1H NMR (500 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.15 (d, J = 5.5 Hz, 1H), 8.05 (s, 1H), 6.81 (d, J = 0.6 Hz, 1H), 6.66 (d, J = 0.6 Hz, 1H), 6.28 (d, J = 5.5 Hz, 1H), 5.11–5.05 (m, 1H), 4.24 (p, J = 6.7 Hz, 1H), 4.09 (dd, J = 13.2, 3.6 Hz, 1H), 3.97 (ddd, J = 12.2, 8.0, 5.7 Hz, 1H), 3.94–3.85 (m, 2H), 3.84–3.69 (m, 3H), 3.69–3.56 (m, 2H), 3.39–3.27 (m, 2H), 3.25 (s, 3H), 2.94 (s, 3H), 2.85–2.75 (m, 1H), 2.20 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 2.09–2.02 (m, 1H), 1.88–1.81 (m, 1H), 1.40 (d, J = 6.8 Hz, 3H), 0.95 (dd, J = 25.0, 7.0 Hz, 6H). ESI-MS m / z: 560.3 [M+H] + 。
[0223] Compound S116: 11H NMR (500 MHz, DMSO-d6) δ 9.02 (s, 1H), 8.66 (d, J = 5.5 Hz, 1H), 8.53 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.53 (d, J = 5.8 Hz, 1H), 6.90 (s, 1H), 6.68 (s, 1H), 4.85 (dq, J = 12.6, 6.3 Hz, 1H), 3.85 (dd, J = 9.2, 5.5 Hz, 1H), 3.75–3.66 (m, 2H), 3.63 (dd, J = 9.2, 5.5 Hz, 1H), 3.35 (d, J = 6.2 Hz, 2H), 2.96 (s, 3H), 2.60 (dt, J = 11.4, 5.7 Hz, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.58–1.45 (m, 8H), 1.21–1.12 (m, 2H). ESI-MS m / z: 571.2 [M+H] + 。
[0224] Compound S117: 1 1H NMR (500 MHz, DMSO-d6) δ 9.02 (s, 1H), 8.66 (d, J = 5.5 Hz, 1H), 8.52 (d, J = 1.0 Hz, 1H), 8.41 (s, 1H), 8.16 (s, 1H), 7.53 (d, J = 5.8 Hz, 1H), 6.84 (s, 1H), 6.68 (s, 1H), 4.82 (h, J = 6.4 Hz, 1H), 4.21 (p, J = 6.7 Hz, 1H), 3.91 (dd, J = 9.3, 6.9 Hz, 1H), 3.77 (dd, J = 9.3, 5.7 Hz, 1H), 3.33 (dd, J = 6.2, 3.1 Hz, 2H), 2.94 (s, 3H), 2.83–2.73 (m, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.58–1.47 (m, 5H), 1.45 (d, J = 6.4 Hz, 3H), 1.38 (d, J = 6.8 Hz, 3H), 1.14 (ddd, J = 10.4, 8.9, 5.5 Hz, 2H). ESI-MS m / z: 585.2 [M+H] + 。
[0225] Compound S118: 11H NMR (500 MHz, DMSO-d6) δ 8.98 (s, 1H), 8.66 (d, J = 5.5 Hz, 1H), 8.53 (s, 1H), 8.41 (s, 1H), 8.17 (s, 1H), 7.53 (d, J = 5.8 Hz, 1H), 6.85 (s, 1H), 6.68 (d, J = 0.6 Hz, 1H), 4.64–4.59 (m, 1H), 4.04–3.93 (m, 2H), 3.78 (dd, J = 9.2, 5.8 Hz, 1H), 3.39–3.27 (m, 2H), 2.94 (s, 3H), 2.85–2.74 (m, 1H), 1.98–1.84 (m, 2H), 1.76–1.71 (m, 1H), 1.53–1.49 (m, 2H), 1.41 (d, J = 6.8 Hz, 3H), 1.35 (d, J = 6.4 Hz, 3H), 1.19–1.10 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H). ESI-MS m / z: 599.2 [M+H] + 。
[0226] Compound S119: 1 1H NMR (500 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.66 (d, J = 5.8 Hz, 1H), 8.51 (s, 1H), 8.41 (s, 1H), 8.14 (d, J = 0.6 Hz, 1H), 7.53 (d, J = 5.8 Hz, 1H), 7.11 (d, J = 0.6 Hz, 1H), 6.68 (s, 1H), 4.34–4.26 (m, 1H), 4.19 (p, J = 6.6 Hz, 1H), 3.91 (dd, J = 9.2, 6.8 Hz, 1H), 3.76 (dd, J = 9.3, 5.7 Hz, 1H), 3.39–3.27 (m, 2H), 2.95 (s, 3H), 2.80 (h, J = 6.3 Hz, 1H), 2.68 (p, J = 5.5 Hz, 1H), 1.94–1.85 (m, 2H), 1.79–1.73 (m, 4H), 1.71–1.61 (m, 1H), 1.62 (dddd, J = 6.6, 4.1, 2.9, 1.2 Hz, 1H), 1.51–1.44 (m, 2H), 1.37 (d, J = 6.8 Hz, 3H), 1.24–1.17 (m, 2H). ESI-MS m / z: 611.2 [M+H] + 。
[0227] Compound S120: 11H NMR (500 MHz, DMSO-d6) δ 8.75 (d, J = 0.6 Hz, 1H), 8.18–8.11 (m, 2H), 7.91 (s, 1H), 6.72 (d, J = 0.6 Hz, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.13–5.01 (m, 2H), 4.19 (p, J = 6.7 Hz, 1H), 4.00–3.89 (m, 2H), 3.84–3.70 (m, 2H), 3.67–3.52 (m, 3H), 3.33 (dd, J = 6.1, 2.9 Hz, 2H), 3.26 (s, 3H), 2.94 (s, 3H), 2.79 (d, J = 5.1 Hz, 3H), 2.77–2.67 (m, 1H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.91 (dddd, J = 13.5, 7.9, 5.7, 3.6 Hz, 1H), 1.51 (dd, J = 25.0, 6.4 Hz, 6H), 1.33 (d, J = 6.6 Hz, 3H). ESI-MS m / z: 603.3 [M+H] + 。
[0228] Compound S121: 1 1H NMR (500 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.16 (d, J = 5.5 Hz, 1H), 7.93 (s, 1H), 7.13 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.06 (h, J = 6.3 Hz, 1H), 4.75–4.70 (m, 1H), 4.13–3.94 (m, 3H), 3.83–3.77 (m, 1H), 3.80–3.70 (m, 1H), 3.67–3.49 (m, 3H), 3.33 (dd, J = 6.1, 1.0 Hz, 2H), 3.25 (s, 3H), 3.02 (s, 6H), 2.94 (s, 3H), 2.71 (h, J = 6.3 Hz, 1H), 2.21–2.17 (m, 1H), 1.91–1.86 (m, 1H), 1.51 (dd, J = 25.0, 6.4 Hz, 6H), 1.24 (d, J = 6.8 Hz, 3H). ESI-MS m / z: 617.3 [M+H] + 。
[0229] Compound S122: 11H NMR (500 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.18–8.11 (m, 2H), 7.94 (s, 1H), 6.72 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.08 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 4.60 (p, J = 6.3 Hz, 1H), 4.04–3.94 (m, 2H), 3.88–3.55 (m, 7H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.95 (s, 3H), 2.89–2.77 (m, 4H), 2.20 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.92 (dddd, J = 13.5, 7.9, 5.7, 3.6 Hz, 1H), 1.51 (d, J = 6.4 Hz, 6H). ESI-MS m / z: 589.3 [M+H] + 。
[0230] Compound S123: 1 1H NMR (500 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.41 (t, J = 4.3 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.00 (s, 1H), 6.72 (d, J = 0.6 Hz, 1H), 6.27 (d, J = 5.5 Hz, 1H), 4.66–4.55 (m, 2H), 4.29 (p, J = 6.7 Hz, 1H), 4.08–3.95 (m, 2H), 3.84–3.69 (m, 2H), 3.68–3.50 (m, 4H), 3.40–3.27 (m, 2H), 3.26 (s, 3H), 3.19 (dtd, J = 14.3, 5.6, 4.4 Hz, 1H), 2.94 (s, 3H), 2.81–2.67 (m, 2H), 2.67–2.50 (m, 4H), 2.37 (dt, J = 12.6, 5.6 Hz, 1H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.92–1.87 (m, 1H), 1.51 (dd, J = 25.0, 6.2 Hz, 6H), 1.40 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.2 Hz, 6H). ESI-MS m / z: 688.4 [M+H] + 。
[0231] Compound S124: 11H NMR (500 MHz, DMSO-d6) δ 9.52 (s, 1H), 8.75 (s, 1H), 8.16 (d, J = 5.5 Hz, 1H), 7.99 (s, 1H), 7.60 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 4.71–4.56 (m, 3H), 3.96 (ddd, J = 12.2, 8.1, 5.8 Hz, 1H), 3.91–3.52 (m, 12H), 3.35 (d, J = 6.1 Hz, 2H), 3.26 (s, 3H), 2.95 (s, 3H), 2.84–2.78 (m, 1H), 2.21–2.16 (m, 1H), 1.89–1.84 (m, 1H), 1.51 (d, J = 6.2 Hz, 6H). ESI-MS m / z: 635.3 [M+H] + 。
[0232] Compound S125: 1 1H NMR (500 MHz, DMSO-d6) δ 8.68 (d, J = 0.6 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 7.86 (s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 0.6 Hz, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.11–4.96 (m, 2H), 4.17 (p, J = 6.7 Hz, 1H), 4.00–3.89 (m, 2H), 3.84–3.78 (m, 1H), 3.81–3.70 (m, 1H), 3.67–3.53 (m, 3H), 3.33 (dd, J = 6.3, 2.7 Hz, 2H), 3.26 (s, 3H), 2.95 (s, 3H), 2.74 (h, J = 6.5 Hz, 1H), 2.20 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.92–1.81 (m, 1H), 1.51 (dd, J = 25.0, 6.4 Hz, 6H), 1.31 (d, J = 6.8 Hz, 3H). ESI-MS m / z: 589.3 [M+H] + 。
[0233] Compound S126: 11H NMR (500 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.31 (t, J = 4.4 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 7.94 (s, 1H), 6.72 (d, J = 0.6 Hz, 1H), 6.27 (d, J = 5.5 Hz, 1H), 4.66–4.55 (m, 2H), 4.12 (p, J = 6.7 Hz, 1H), 3.98–3.89 (m, 2H), 3.81–3.54 (m, 5H), 3.40–3.28 (m, 4H), 3.25 (s, 3H), 2.97 (s, 4H), 2.51 (dt, J = 12.8, 5.5 Hz, 1H), 2.44 (dt, J = 12.8, 5.5 Hz, 1H), 2.22 (s, 6H), 2.26–2.16 (m, 1H), 1.93–1.88 (m, 1H), 1.51 (dd, J = 25.0, 6.4 Hz, 6H), 1.39 (d, J = 6.8 Hz, 3H). ESI-MS m / z: 660.3 [M+H] + 。
[0234] Compound S127: 1 1H NMR (500 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.76 (s, 1H), 8.67 (d, J = 5.8 Hz, 1H), 8.41 (s, 1H), 8.25–8.15 (m, 2H), 7.53 (d, J = 5.8 Hz, 1H), 6.69 (s, 1H), 4.60 (dq, J = 12.6, 6.3 Hz, 1H), 4.20 (p, J = 6.7 Hz, 1H), 3.95 (dd, J = 9.2, 6.8 Hz, 1H), 3.82 (dd, J = 9.2, 5.8 Hz, 1H), 3.34 (dd, J = 6.1, 2.2 Hz, 2H), 2.95 (s, 3H), 2.84–2.74 (m, 4H), 1.88 (p, J = 5.5 Hz, 1H), 1.57–1.46 (m, 8H), 1.37 (d, J = 6.6 Hz, 3H), 1.18–1.09 (m, 2H). ESI-MS m / z: 642.2 [M+H] + 。
[0235] Compound S128: 11H NMR (500 MHz, DMSO-d6) δ 8.71–8.64 (m, 2H), 8.60 (s, 1H), 8.41 (s, 1H), 8.17 (d, J = 0.6 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.56–7.47 (m, 2H), 6.69 (s, 1H), 4.46 (p, J = 6.4 Hz, 1H), 3.94 (dd, J = 9.2, 5.5 Hz, 1H), 3.81 (dd, J = 9.2, 5.5 Hz, 1H), 3.71 (dd, J = 9.2, 5.5 Hz, 1H), 3.63 (dd, J = 9.0, 5.6 Hz, 1H), 3.35 (d, J = 6.1 Hz, 2H), 2.94 (s, 3H), 2.82 (dq, J = 11.5, 5.6 Hz, 1H), 1.88 (p, J = 5.5 Hz, 1H), 1.56–1.47 (m, 8H), 1.23 (tdd, J = 9.7, 5.5, 0.7 Hz, 2H). ESI-MS m / z: 614.2 [M+H] + 。
[0236] Compound S129: 1 1H NMR (500 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.05 (s, 1H), 7.03 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.11 (hept, J = 6.4 Hz, 1H), 4.65 (ddd, J = 4.1, 3.2, 1.7 Hz, 1H), 4.03–3.97 (m, 1H), 4.01–3.88 (m, 2H), 3.82 (d, J = 13.2 Hz, 1H), 3.81–3.68 (m, 2H), 3.65–3.48 (m, 8H), 3.40–3.26 (m, 2H), 3.23 (s, 3H), 2.94 (s, 3H), 2.89–2.79 (m, 1H), 2.52–2.42 (m, 4H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.90–1.85 (m, 1H), 1.49 (dd, J = 25.0, 6.4 Hz, 6H), 1.34 (d, J = 6.6 Hz, 3H). ESI-MS m / z: 645.3 [M+H] + 。
[0237] Compound S130: 11H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 0.6 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.07 (s, 1H), 7.42 (tt, J = 5.8, 4.1 Hz, 1H), 6.69 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.07 (hept, J = 6.3 Hz, 1H), 4.66–4.60 (m, 1H), 4.27 (t, J = 7.3 Hz, 1H), 4.19 (dd, J = 15.0, 5.8 Hz, 1H), 4.05 (dd, J = 9.3, 6.9 Hz, 1H), 4.03–3.93 (m, 3H), 3.81–3.48 (m, 7H), 3.39–3.27 (m, 2H), 3.25 (s, 3H), 2.95 (s, 3H), 2.98–2.87 (m, 1H), 2.85–2.74 (m, 2H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.91–1.85 (m, 1H), 1.50 (dd, J = 25.0, 6.4 Hz, 6H), 1.38 (d, J = 6.6 Hz, 3H). ESI-MS m / z: 619.3 [M+H] + 。
[0238] Compound S131: 1 1H NMR (500 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.07 (s, 1H), 7.02 (tt, J = 6.0, 4.1 Hz, 1H), 6.69 (d, J = 0.6 Hz, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.16–5.05 (m, 1H), 5.01–4.96 (m, 1H), 4.19 (dd, J = 15.0, 5.8 Hz, 1H), 4.02–3.55 (m, 11H), 3.44 (t, J = 5.2 Hz, 2H), 3.37–3.32 (m, 4H), 3.26 (s, 3H), 2.96 (s, 3H), 2.94–2.77 (m, 3H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.89–1.85 (m, 1H), 1.50 (d, J = 6.4 Hz, 6H). ESI-MS m / z: 619.3 [M+H] + 。
[0239] Compound S132: 11H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J = 0.6 Hz, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.05 (s, 1H), 6.69 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.12 (p, J = 6.3 Hz, 1H), 4.68–4.62 (m, 1H), 4.03–3.89 (m, 3H), 3.81–3.69 (m, 2H), 3.68–3.48 (m, 5H), 3.40–3.26 (m, 2H), 3.23 (s, 3H), 2.94 (s, 3H), 2.83 (h, J = 6.4 Hz, 1H), 2.54–2.48 (m, 4H), 2.43–2.36 (m, 4H), 2.24 (s, 3H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.90 (dddd, J = 13.5, 7.9, 5.7, 3.6 Hz, 1H), 1.49 (dd, J = 25.0, 6.4 Hz, 6H), 1.34 (d, J = 6.8 Hz, 3H). ESI-MS m / z: 658.4 [M+H] + .
[0240] Compound S133: 1 1H NMR (500 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.02 (s, 1H), 6.69 (s, 1H), 6.27 (d, J = 5.8 Hz, 1H), 5.10 (hept, J = 6.3 Hz, 1H), 4.65–4.59 (m, 1H), 4.56–4.50 (m, 1H), 4.00 (dd, J = 9.2, 5.6 Hz, 1H), 3.95 (ddd, J = 12.2, 8.1, 5.8 Hz, 1H), 3.83 (dd, J = 9.2, 5.6 Hz, 1H), 3.82–3.70 (m, 2H), 3.74–3.63 (m, 2H), 3.66–3.57 (m, 3H), 3.60–3.51 (m, 1H), 3.35 (d, J = 6.1 Hz, 2H), 3.24 (s, 3H), 2.96 (s, 3H), 2.83 (hept, J = 5.7 Hz, 1H), 2.70–2.59 (m, 4H), 2.57–2.44 (m, 5H), 2.36 (dq, J = 12.2, 7.2 Hz, 1H), 2.21 (ddt, J = 13.7, 7.9, 5.8 Hz, 1H), 1.87–1.81 (m, 1H), 1.49 (d, J = 6.4 Hz, 5H), 1.01 (t, J = 7.2 Hz, 3H). ESI-MS m / z: 658.4 [M+H] +.
[0241] Compound S134: 1 H NMR(500MHz,DMSO-d6)δ8.94(s,1H),8.66(d,J=5.6Hz,1H),8.60(s,1H),8.41(s,1H),8.17(d,J=0.6Hz ,1H),7.53(d,J=5.8Hz,1H),6.66(s,1H),4.78(dq,J=12.6,6.3Hz,1H),3.96–3.83(m,2H),3.86–3.77(m ,2H),3.67(d,J=13.2Hz,1H),3.57(t,J=6.0Hz,4H),3.41–3.27(m,2H),2.97(s,3H),2.88–2.78(m,1H) ,2.56–2.42(m,4H),1.88(p,J=5.5Hz,1H),1.57–1.44(m,8H),1.40(d,J=6.8Hz,3H),1.19–1.10(m,2H). ESI-MS m / z:684.3[M+H] + .
[0242] Compound S135: 1 H NMR (500MHz, DMSO-d6) δ8.94(s,1H),8.66(d,J=5.6Hz,1H),8.59(s,1H),8.41(s,1H),8.17(d,J=0.6Hz,1H),7.53(d,J=5 .8Hz,1H),6.65(s,1H),4.79(p,J=6.4Hz,1H),4.27(p,J=6.6Hz,1H),3.93(dd,J=9.4,6.8Hz,1H),3.85–3.75(m,2H),3.6 3(d,J=13.2Hz,1H),3.33(dd,J=6.3,2.0Hz,2H),2.94(s,3H),2.78(h,J=6.5Hz,1H),2.54–2.48(m,4H),2.42–2.36(m,4H ),2.23(s,3H),1.88(p,J=5.5Hz,1H),1.57–1.48(m,5H),1.47(d,J=6.4Hz,3H),1.40(d,J=6.6Hz,3H),1.19–1.10(m,2H). ESI-MS m / z:697.3[M+H] + .
[0243] Compound S136: 1H NMR (500MHz, DMSO-d6) δ8.95(s,1H),8.66(d,J=5.8Hz,1H),8.58(d,J=0.6Hz,1H),8.41(s,1H),8.17(d,J=0.6Hz,1H),7.53(d,J =5.8Hz,1H),7.02(tt,J=6.0,4.1Hz,1H),6.65(s,1H),5.15(hept,J=6.4Hz,1H),4.20(dd,J=15.0,6.0Hz,1H),4.06(dd,J=15.0, 5.8Hz,1H),3.98–3.88(m,2H),3.78(dd,J=9.3,5.7Hz,1H),3.52(dt,J=12.4,5.2Hz,1H),3.42–3.27(m,3H),3.34(s,3H),2.94( s,3H),2.98–2.88(m,1H),2.88–2.74(m,2H),1.88(p,J=5.5Hz,1H),1.57–1.45(m,8H),1.39(d,J=6.8Hz,3H),1.19–1.10(m,2H). ESI-MS m / z:672.3[M+H] + .
[0244] Example 4: Effects of Compounds on EGFR L858R / T790M / C797S , EGFR del19 / T790M / C797S Evaluation of inhibitory activity of mutant kinases
[0245] Experimental method: This experiment uses the HTRF kinase assay method, the substrate peptide TK and ATP are in the tyrosine kinase EGFR L858R / T790M / C797S EGFR del19 / T790M / C797S In the presence of mutations, a catalytic reaction occurs and the substrate is phosphorylated. The activity of the kinase is characterized by measuring the content of the phosphorylated substrate generated in the reaction, and the effect of the compound on EGFR is obtained. L858R / T790M / C797S EGFR del19 / T790M / C797S IC50 inhibitory concentration of mutant kinase activity 50 .
[0246] Experimental steps: Kinase reaction was carried out in a white 384-well plate (Perkin Elmer #600828000). 1-5 μL of different concentrations of compounds diluted with ultrapure water containing 1% DMSO were added to each well. 1-5 μL of ultrapure water containing 1% DMSO was added to the positive control wells. Then, 1-5 μL of 0.5-5 nM 4× EGFR diluted with Dilution buffer (5× kinase buffer, MgCl2 6.65 Mm, MnCl2 1.33 mM, DTT 1.33 mM) was added to each well.L858R / T790M / C797S EGFR del19 / T790M / C797S For the mutant kinase solution, add 1-5 μL of Dilution buffer to the negative control wells, add 1-5 μL of 4 μM 4× substrate TK solution prepared with 10× Dilution buffer to all wells, and finally add 1-5 μL of 24 μM 4× ATP solution diluted with Dilution buffer to start the reaction. After reacting at room temperature for 120 minutes, add 10 μL of detection solution (TK antibody 16 nM) to each well and react at room temperature in the dark for 120 minutes, then use BioTek Synergy H1 microplate reader to detect the chemiluminescence value.
[0247] The log(inhibitor) vs.response-Variableslope analysis software GraphPad Prism 5 was used to fit the dose-effect curve to obtain the IC value of each compound on the enzyme activity. 50 The resulting IC 50 The values are shown in Table 1. From the results, it can be seen that the compounds of the present invention have strong EGFR L858R / T790M / C797S EGFR del19 / T790M / C797S Kinase inhibitory activity (Tables 1-2).
[0248] Table 1. EGFR L858R / T790M / C797S Kinase inhibitory activity
[0249]
[0250]
[0251]
[0252] Table 2. EGFR del19 / T790M / C797S Kinase inhibitory activity
[0253]
[0254]
[0255]
[0256] The above data show that the compounds of the present invention have an L858R / T790M / C797S and EGFR del19 / T790M / C797S Excellent inhibitory activity against drug-resistant mutant kinases, IC 50 The value reaches the nanomolar concentration level, the optimal picomolar concentration level, and the activity is better than or equal to the positive control drug.
[0257] Example 5: Effects of Compounds on H-1975 (EGFR L858R / T790M / C797S )、PC-9(EGFRdel19 / T790M / C797S ) cell line cell proliferation inhibitory activity evaluation
[0258] Experimental steps: After counting the cells, inoculate 100 μL of cell suspension in a 96-well plate. Culture in the incubator for one day, add the corresponding concentration of compound after the cells adhere, dissolve the compound with 100% DMSO and prepare a 1 mM solution, and then dilute the compound to the required concentration with culture medium. Add 100 μL of compound solution to the 96-well plate and blow evenly. After placing the 96-well plate in a cell culture incubator and culturing for 72 hours, add 100 μL of Cell Count Kit 8 reagent to each well of the 96-well plate, place the 96-well plate in a cell culture incubator and culture for 4 hours, and read the fluorescence value with an enzyme reader. Use the inhibitor vs. response-Variable slope (four parameters) of the analysis software GraphPadPrism 7 to fit the dose-effect curve, so as to obtain the IC value of each compound's inhibitory activity on cell proliferation. 50 Values (Table 3-Table 4).
[0259] Table 3. Effects of compounds on H-1975 (EGFR L858R / T790M / C797S ) Cell proliferation inhibition IC 50
[0260]
[0261]
[0262] Table 4. Effects of compounds on PC-9 (EGFR del19 / T790M / C797S ) Cell proliferation inhibition IC 50
[0263]
[0264] The above data show that the compounds of the present invention have an L858R / T790M / C797S ) and PC-9 (EGFR del19 / T790M / C797S ) cell proliferation has excellent inhibitory activity, IC 50 The value reached the nanomolar concentration level, and the activity was better than or equal to the positive control drug.
Claims
1. A pyrimidine compound, It is characterized in that Having the structure of formula (I), and also including pharmaceutically acceptable salts, stereoisomers, deuterated compounds or mixtures thereof: in: m is selected from 0 or 1; when m is 1, M 1 C, M 2 is CH; when m is 0, M 1 is N; X is selected from O or NH; A is selected from unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 Aryl, OR 2 , SR 2 NR 2 R 3 ; The heteroatom is N, O or S; R 1 Selected from hydroxy, cyano, halogen, nitro, C 1-6 Alkyl, C 2-8 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 6-10 Aryloxy, heteroaryloxy, (C 3-10 Cycloalkyl)-oxy, halo (C 1-6 Alkyl), hydroxyl (C 1-6 Alkyl), amino (C 1-6 Alkyl), C 1-6 Alkylamino-C 1-6 Alkoxy-, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-(C 1-6 Alkyl)-, C 3-10 Cycloalkyl-(C 1-6 Alkoxy), -OCD 3 、-NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR 1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 , -O(C=O)R 1-12 、-S(=O) 2 NR 1-13 R 1-14 、-NR 1-15 S(=O) 2 R 1-16 、-S(=O) 2 R 1-17 or -P(=O)R 1-18 R 1-19 , unsubstituted or R 1-1 Substituted C 6-10 Aryl, C 6-10 Aryl-(C 1-6 alkyl)-, unsubstituted or R 1-2 Substituted C 6-10 Aryl-(C 1-6 alkoxy)-, heterocycloalkyl, heterocycloalkyl-(C 1-6 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-6 alkyl)- or heteroaryl-(C 1-6 The heterocycloalkyl group is a 4- to 10-membered heterocycloalkyl group having 1 to 4 heteroatoms; the heteroaryl group is a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms; R 1-1 ~R 1-3 Any one independently selected from C 1-4 Alkyl, hydroxyl (C 1-4 alkyl)-, halogen, cyano, hydroxyl, C 1-4 Alkylamino, C 1-4 Alkoxy or halogenated (C 1-4 Alkyl)-; R 1-4 ~R 1-19 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 The heteroatom is N, O or S; R 2 Selected from C 3-10 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-6 Alkyl, unsubstituted or R 2-2 Substituted C 6-10 Aryl, 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O) 2 NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O) 2 R 2-1-13 、-S(=O) 2 R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 The heteroatom is N, O or S; R 3 Selected from hydrogen or C 1-4 alkyl; R 4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl or C 3-10 Cycloalkyl-(C 1-6 Alkyl)-; R 4-1 Selected from halogen, hydroxyl, NR 4-1-1 R 4-1-2 or cyano; R 4-1-1 , R 4-1-2 Any one independently selected from hydrogen or C 1-6 alkyl; R 5 , R 6 independently selected from hydrogen, methyl or ethyl; R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl having 1 to 4 heteroatoms; R 7-1 Selected from halogen, cyano, hydroxyl, NR 7-1-1 R 7-1-2 , C 1-6 Alkyl or C 1-6 Alkoxy; R 7-1-1 , R 7-1-2 Any one independently selected from hydrogen or C 1-6 Alkyl; the heteroatom is N, O or S; R 8 Selected from hydrogen or C 1-4 alkyl; R 9 Selected from hydrogen, -NHR 9-1 、-C=ONH 2 、-C=ONHR 9-1 , -C=ONR 9-1 R 9-2 、-C=ONHO(CH 2 )nOH, -CH 2 NH(CH 2 )n 9-1 、-C=ONH(CH 2 ) 9-1 R 9-2 、-CH 2 R 9 -1 , unsubstituted or at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 10 membered heterocycloalkyl, 3 to 10 membered heterocycloalkyl-NR 9-4-1 -, (3- to 10-membered heterocycloalkyl)-(3- to 10-membered heterocycloalkyl)-, 6- to 17-membered spiro heterocyclic group, 6- to 17-membered bridged heterocyclic group, 6- to 17-membered bis-heterocyclic group; R 9-1 ~R 9-3 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl, unsubstituted or substituted with one or more R 9-1-1 A 4- to 10-membered heterocycloalkyl group having 1 to 4 substituted heteroatoms, wherein the heteroatoms are N, O or S; R 9-4 Selected from H, halogen, -OH, -NH 2 , C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -NHR 9-4-1 、-NR 9-4-1 R 9-4-2 , -C 1-4 Alkyl-NR 9-4-1 R 9-4-2 、-NR 9-4-1 R 9-4-2 -C 1-4 Alkyl-NR 9-4-3 R 9-4-4 ; n is an integer selected from 1 to 4; R 9-1-1 , R 9-4-1 ~R 9-4-4 Any one independently selected from hydrogen, C 1-4 alkyl; and when m is 1, R 9 Not hydrogen.
2. The pyrimidine compound and its derivative according to claim 1, It is characterized in that In the structure: When A is unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 When the aryl group is C 5-8 Aryl; the heteroatom is N, O or S; R 1 Selected from hydroxy, cyano, halogen, nitro, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 6-10 Aryloxy, heteroaryloxy, (C 3-7 Cycloalkyl)-oxy, halo (C 1-4 Alkyl), hydroxyl (C 1-4 Alkyl), amino (C 1-4 Alkyl), C 1-4 Alkylamino-C 1-4 Alkoxy-, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-(C 1-4 Alkyl)-, C 3-7 Cycloalkyl-(C 1-4 Alkoxy), -OCD3, -NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR 1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 , -O(C=O)R 1-12 、-S(=O) 2 NR 1-13 R 1-14 、-NR 1-15 S(=O) 2 R 1-16 、-S(=O) 2 R 1-17 or -P(=O)R 1-18 R 1-19 , unsubstituted or R 1-1 Substituted C 6-10 Aryl, C 6-10 Aryl-(C 1-4 alkyl)-, unsubstituted or R 1-2 Substituted C 6-10 Aryl-(C 1-4 alkoxy)-, heterocycloalkyl, heterocycloalkyl-(C 1-4 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-4 alkyl)- or heteroaryl-(C 1-4 The heterocycloalkyl group is a 4- to 8-membered heterocycloalkyl group having 1 to 3 heteroatoms; the heteroaryl group is a 5- to 8-membered heteroaryl group having 1 to 3 heteroatoms; R 1-1 ~R 1-3 Any one independently selected from C 1-4 Alkyl, hydroxyl (C 1-4 alkyl)-, halogen, cyano, hydroxyl, C 1-4 Alkylamino, C 1-4 Alkoxy or halogenated (C 1-4 Alkyl)-; R 1-4 ~R 1-19 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S; When A is OR 2 , SR 2 NR 2 R 3 When R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1- 4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O) 2 NR 2-1-10 R 2-1-11 、-NR 2-1- 12 S(=O) 2 R 2-1-13 、-S(=O) 2 R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S; R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, C 1-6 Alkyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2-1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2 -1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O) 2 NR 2-1-10 R 2-1-11 、-NR 2-1-12 S(=O) 2 R 2-1-13 、-S(=O) 2 R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one independently selected from hydrogen, C 1-4 Alkyl, C 3-10 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 The heteroatom is N, O or S; R 4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 Alkyl)-; R 4-1 Selected from halogen, hydroxyl, NR 4-1-1 R 4-1-2 or cyano; R 4-1-1 , R 4-1-2 Any one independently selected from hydrogen or C 1-4 alkyl; R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or 4- to 8-membered heterocycloalkyl having 1 to 3 heteroatoms; R 7-1 Selected from halogen, cyano, hydroxyl, NR 7-1-1 R 7-1-2 , C 1-4 Alkyl or C 1-4 Alkoxy; R 7-1-1 , R 7-1-2 Any one independently selected from hydrogen or C 1-4 Alkyl; the heteroatom is N, O or S; R 9 Selected from hydrogen, -NHR 9-1 、-C=ONH 2 、-C=ONHR 9-1 , -C=ONR 9-1 R 9-2 、-C=ONHO(CH 2 )nOH, -CH 2 NH(CH 2 )n 9-1 、-C=ONH(CH 2 ) 9-1 R 9-2 、-CH 2 R 9 -1 , unsubstituted or at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 7 membered heterocycloalkyl, 3 to 7 membered heterocycloalkyl-NR 9-4-1 -, (3- to 7-membered heterocycloalkyl)-(3- to 7-membered heterocycloalkyl)-, 6- to 14-membered spiro heterocyclic group, 6- to 14-membered bridged heterocyclic group, 6- to 14-membered fused heterocyclic group; R 9-1 ~R 9-3 Any one independently selected from hydrogen, C 1-3 Alkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more R 9-1-1 A 4- to 8-membered heterocycloalkyl group having 1 to 3 substituted heteroatoms, wherein the heteroatoms are N, O or S; R 9-4 Selected from H, halogen, -OH, -NH 2 , C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-3 Alkyl, -NHR 9-4-1 、-NR 9-4-1 R 9-4-2 , -C 1-4 Alkyl-NR 9-4-1 R 9-4-2 、-NR 9-4-1 R 9-4-2 -C 1-4 Alkyl-NR 9-4-3 R 9-4-4 ; n is an integer selected from 1 to 3; R 9-1-1 , R 9-4-1 ~R 9-4-4 Any one independently selected from hydrogen, C 1-4 alkyl; and when m is 1, R 9 Not hydrogen.
3. The pyrimidine compound and its derivative according to claim 1, It is characterized in that In the structure: R 4 is selected from hydrogen, unsubstituted or R 4-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or C 3-7 Cycloalkyl-(C 1-4 Alkyl)-; R 4-1 is selected from fluorine, chlorine, bromine, hydroxyl, methylamine, ethylamine, dimethylamine, diethylamine, n-propylamine or cyano; R 5 , R 6 independently selected from hydrogen or methyl; R 7 is selected from hydrogen, unsubstituted or R 7-1 Substituted C 1-4 Alkyl, C 3-7 Cycloalkyl or 4-8 membered heterocycloalkyl having 1-3 heteroatoms; the heteroatoms are N, O or S; R 7-1 is selected from halogen, cyano, hydroxy, methylamino, ethylamino, dimethylamino, diethylamino, propylamino, methyl, ethyl, n-propyl, isopropyl, methoxy or ethoxy; R 9 Selected from hydrogen, -NHR 9-1 、-C=ONH 2 、-C=ONHR 9-1 , -C=ONR 9-1 R 9-2 、-C=ONHO(CH 2 )nOH, -CH 2 NH(CH 2 )n 9-1 、-C=ONH(CH 2 ) 9-1 R 9-2 、-CH 2 R 9 -1 , unsubstituted or replaced by at least one R 9-4 Substituted ring structures containing 1 to 4 N, O or S heteroatoms: 3 to 7 membered heterocycloalkyl, 3 to 7 membered heterocycloalkyl-NR 9-4-1 -, (3- to 7-membered heterocycloalkyl)-(3- to 7-membered heterocycloalkyl)-, 6- to 14-membered spiro heterocyclic group, 6- to 14-membered bridged heterocyclic group, 6- to 14-membered fused heterocyclic group; R 9-1 ~R 9-3 Any one is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, unsubstituted or substituted by one or more R 9-1-1 Substituted morpholine, pyrrole, piperidine, piperazine, pyran; R 9-4 Selected from H, halogen, -OH, -NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, -CH 2 Cl, -CH 2 CH 2 Cl, -CH 2 CH 2 Br, -CH 2 CH 2 OH, -CH 2 OH, -CH 2 CH 2 OCH 3 、-CH 2 OCH 3 、-NHCH 3 、-NHCH 2 CH 3 、-NHCH(CH 3 ) 2 、-N(CH 3 ) 2 、-N(CH 2 CH 3 ) 2 、-NCH 3 CH 2 CH 3 、-CH 2 NH 2 、-CH 2 NHCH 3 、 -CH 2 N(CH 3 ) 2 、 -CH 2 N(CH 2 CH 3 ) 2 、 -(CH 2 ) 2 NH 2 、 -(CH 2 ) 2 NHCH 3 、 -(CH 2 ) 2 N(CH 3 ) 2 、 -(CH 2 ) 2 N(CH 2 CH 3 ) 2 、 -(CH 2 ) 2 NCH 3 CH 2 CH 3 、 -(CH 2 ) 3 NH 2 、 -(CH 2 ) 3 NHCH 3 、 -(CH 2 ) 3 N(CH 3 ) 2 、 -(CH 2 ) 3 N(CH 2 CH 3 ) 2 、 -(CH 2 ) 3 NCH 3 CH 2 CH 3 、 -NCH 3 CH 2 CH 2 N(CH 3 ) 2 、 -NCH 3 CH 2 CH 2 CH 2 N(CH 3 ) 2 ; n is an integer selected from 1 to 3; R 9-1-1 、 R 9-4-1 ~ R 9-4-4 are independently selected from hydrogen, methyl, ethyl, isopropyl; and when m is 1, R 9 Not hydrogen.
4. The pyrimidine compound according to claim 1, It is characterized in that In the structure: When A is unsubstituted or R 1 substituted 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl having 1 to 4 heteroatoms, C 5-10 When the aryl group is aryl, the substituent is selected from hydroxyl, cyano, halogen, nitro, C 1-4 Alkyl, C 1-4 Alkoxy, hydroxyl (C 1-4 Alkyl)-, amino (C 1-4 Alkyl)-, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-(C 1-4 Alkyl)-, C 3-6 Cycloalkyl-(C 1-4 Alkoxy)-, -OCD 3 、-NR 1-4 R 1-5 、-(C=O)R 1-6 、-(C=O)NR 1-7 R 1-8 、-NR 1-9 (C=O)R 1-10 、-(C=O)OR 1-11 , -O(C=O)R 1-12 、-(S=O) 2 NR 1-13 R 1-14 、-NR 1-15 (S=O) 2 R 1-16 、-(S=O) 2 R 1-17 、-(P=O)(CH 3 ) 2 , unsubstituted or R 1-1 Substituted phenyl, phenyl-(C 1-4 alkyl)-, unsubstituted or R 1-2 Substituted heterocycloalkyl, heterocycloalkyl-(C 1-4 alkyl)-, unsubstituted or R 1-3 Substituted heteroaryl, heteroaryl-(C 1-4 alkyl)-; the heterocycloalkyl is a 3- to 10-membered heterocycloalkyl with 1 to 4 heteroatoms; the heteroaryl is a 5- to 10-membered heteroaryl with 1 to 3 heteroatoms; the heteroatom is N, O or S; R 1-1 ~R 1-3 Any one is independently selected from hydrogen, methyl, ethyl, hydroxymethyl, hydroxyethyl, fluorine, chlorine, bromine, cyano, hydroxy, methylamino, ethylamino, methoxy, ethoxy, bromomethyl, bromoethyl, chloromethyl or chloroethyl; R 1-4 ~R 1-19 Any one is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 3-6 Cycloalkyl or C 3-6 Cycloalkyl-(C 1-4 alkyl); When A is OR 2 , SR 2 NR 2 R 3 When R 2 Selected from C 3-7 Cycloalkyl, unsubstituted or R 2-1 Substituted C 1-4 Alkyl, unsubstituted or R 2-2 Substituted C 6-8 Aryl, 4- to 8-membered heterocycloalkyl or 5- to 8-membered heteroaryl having 1 to 3 heteroatoms; R 2-1 , R 2-2 are independently selected from hydrogen, halogen, nitro, cyano, methyl, ethyl, isopropyl, n-propyl, hydroxyl, amino, -NR 2-1-1 R 2-1-2 、-(C=O)R 2 -1-3 、-(C=O)NR 2-1-4 R 2-1-5 、-NR 2-1-6 (C=O)R 2-1-7 、-(C=O)OR 2-1-8 , -O(C=O)R 2-1-9 、-S(=O) 2 NR 2 -1-10 R 2-1-11 、-NR 2-1-12 S(=O) 2 R 2-1-13 、-S(=O) 2 R 2-1-14 or -P(=O)R 2-1-15 R 2-1-16 ; R 2-1-1 ~R 2-1-16 Any one is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, C 3-6 Cycloalkyl or C 3-6 Cycloalkyl-(C 1-4 The heteroatom is N, O or S; R 3 is selected from hydrogen, methyl or ethyl; R 8 is selected from hydrogen, methyl or ethyl.
5. The pyrimidine compound and its derivative according to claim 1, It is characterized in that In the structure: A is selected from any of the following groups: R 9 Selected from any of the following groups:
6. The pyrimidine compound according to claim 1, It is characterized in that Selected from any of the following compounds:
7. A method for preparing the pyrimidine compound according to claim 1, It is characterized in that Compound (I) is prepared by a substitution reaction between compound 1 and compound 2; Among them, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , A, M 1 、M 2 , X, and m are defined as in claim 1; The pharmaceutically acceptable salt is obtained by reacting the corresponding acid with the compound (I) prepared by the above method to form a salt.
8. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the pyrimidine compound according to claim 1 and a pharmaceutically acceptable carrier.
9. Use of the pyrimidine compound according to claim 1 or the pharmaceutical composition according to claim 8 in the preparation of EGFR inhibitor drugs.
10. The use according to claim 9, It is characterized in that The EGFR inhibitor drug is an anti-tumor drug.
